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ABSTRACT 
Although mitochondrial respiratory chain deficiencies (often called “mitochondrial disease”) 
affect an estimated 1 in 5,000 individuals world-wide, prior to the recent diagnosis of this study’s 
index patient, mitochondrial DNA (mtDNA) mutations were not previously reported in Amish 
communities. The index patient from the Northwestern Pennsylvania Amish community was 
diagnosed with MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, Stroke-like 
Episodes), the most common maternally-inherited mitochondrial disorder, and carries the common 
MELAS mutation, m.3243A>G in the MT-TL1 gene. Subsequently, two additional Amish families 
with different mitochondrial mutations were identified. These findings prompted a study with three 
aims: characterizing the incidence and clinical features of this MELAS mutation in this 
community, constructing a detailed pedigree of the Amish community, and assessing by pre- and 
post-intervention questionnaires the efficacy of an educational intervention designed to increase 
understanding of MELAS and mitochondrial disease. 
A study visit to the community was attended by the index patient’s extended family. During 
this visit, an educational intervention was presented, and questionnaires were administered. 
Interviews were conducted to gather family history information, including family structure and the 
presence of mitochondrial disease symptoms in family members. Samples were collected from 13 
adults and two children for genetic testing. Samples were analyzed using high-resolution melt 
profiling for targeted assessment of the m.3243A>G mutation. While data analysis of 
 v 
questionnaires demonstrated limited increased understanding of educational intervention material, 
anecdotal experiences support increased understanding. Genetic testing revealed the mutation of 
interest in 13 participants, with tissue-specific variations in the levels of heteroplasmy. At a follow-
up visit, test results and their implications were disclosed and discussed through genetic 
counseling. 
This study’s findings suggest maternally-inherited mitochondrial disease may be under-
recognized given the lack of previous diagnosis in 13 participants reported here. The public health 
significance demonstrated through this is the potential for similarly unrecognized mitochondrial 
disease in the larger Amish community and in the general population due to the challenges related 
to diagnosis. Results of efficacy analysis of an educational intervention in this community can also 
inform the development of educational interventions for the general population and for health care 
providers about mitochondrial and other rare genetic disease. 
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1.0  INTRODUCTION 
A 15 year-old female first presented to the Children’s Hospital of Pittsburgh of UPMC with acute 
vomiting, altered mental status, status epilepticus, and lactic acidosis. A brain MRI revealed a 
small focal, left occipital lobe infarct, after which she developed other stroke-like episodes in the 
left occipital and temporal areas. It was revealed that she also had a history of developmental delay, 
short stature, hearing loss, fatigability, and poor appetite. Confirmation of a MELAS 
(Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like Episodes) diagnosis was made 
through molecular testing of saliva, which showed 74% heteroplasmy for the most common 
MELAS-causing mutation, m.3243A>G in the MT-LT1 gene. This patient was a member of the 
Mercer County, Pennsylvania Amish community, where mtDNA mutations had not previously 
been identified. This patient’s presentation was coupled with an extensive family history of 
MELAS-related symptoms, including the following: developmental delay, migraine headaches, 
hearing loss, mild hypotonia, renal failure, diabetes mellitus, and recurrent miscarriages. 
Knowledge that a significant portion of patients in the Amish community with chronic disease 
remain undiagnosed1 combined with familiarity with the significant monetary and health-care 
impact of the Clinic for Special Children on the Amish community in Lancaster, Pennsylvania led 
to development of a program to assess the Amish communities of Northwestern Pennsylvania, 
initially for MELAS, but ultimately for other mitochondrial conditions.2; 3 
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Based on identification of MELAS in the community, the potential benefits of early 
diagnosis and treatment, and the recognition that this and other conditions are under-diagnosed in 
this population, investigators developed a study whose aims were three-fold: to characterize the 
incidence and clinical features of this MELAS mutation in this Amish community, to construct a 
detailed extended pedigree of the index family and other key kinships in the community, and to 
assess by pre- and post-intervention questionnaires the efficacy of an educational intervention 
designed to increase understanding of MELAS and mitochondrial disease in this community. 
This document will serve to outline the background information used to design, implement, 
and analyze this study, provide information about the potential significance of this work, detail the 
methods used in the study, and describe and discuss study results. Additionally, the public health 
competencies developed and practiced throughout the study will be considered. Finally, 
conclusions about the study will be presented, as well as information about future directions of 
continued research including further investigation of MELAS and potential identification of other 
mitochondrial disorders in this community and in the general population at large.  
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2.0  HYPOTHESES AND SPECIFIC AIMS 
2.1 HYPOTHESES 
Hypothesis 1: There is a higher incidence of the m.3243A>G mutation in the MT-TL1 gene in 
mitochondrial DNA in the Northwestern Pennsylvania Amish community than is currently 
clinically recognized. 
Hypothesis 2: The proposed educational intervention will increase understanding of MELAS and 
mitochondrial disease in the Northwestern Pennsylvania Amish community. 
2.2 SPECIFIC AIMS 
Aim 1: To characterize the incidence and clinical features of the m.3243A>G MT-TL1 gene 
mutation in the Northwestern Pennsylvania Amish community. 
Aim 2: To construct a detailed extended pedigree of the index family and other key kinships in 
the Northwestern Pennsylvania Amish community. 
Aim 3: To assess the efficacy of an educational intervention designed to increase understanding 
of MELAS and mitochondrial disease in the Northwestern Pennsylvania Amish community using 
pre- and post-intervention surveys. 
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3.0  BACKGROUND 
3.1 MITOCHONDRIA 
Mitochondria are the powerhouse of the cell because they are the cell’s energy-producing 
organelles. Mitochondria synthesize adenosine tri-phosphate (ATP), which is the main energy 
currency of life. Each mitochondrion carries multiple copies of its own DNA called mitochondrial 
DNA, or mtDNA. 
3.1.1 Mitochondrial Energy Production 
A key function of mitochondria is to synthesize ATP via oxidative phosphorylation (OXPHOS), 
as shown in Figure 1.4 As much as 90% of the body’s energy is produced as mitochondria convert 
reducing equivalents from cellular metabolism plus oxygen into ATP.5 The carbohydrates 
consumed by an individual begin the energy conversion process through glycolysis, and the 
products of this reaction enter the tricarboxylic acid (TCA) cycle. During times of stress or fasting, 
fatty acids are oxidized inside the mitochondrion to produce NADH+, hydrogen ions, electrons, 
and FADH2. The products go through OXPHOS via respiratory complexes I, II, III, and IV to 
produce water.6 Flow through the electron transport chain is used to create an electrochemical 
gradient that allows for the storage of potential energy, which is later used to bring proteins and 
calcium into the mitochondrion, to generate heat, and to synthesize ATP inside the mitochondrial 
matrix.7 
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Figure 1. Oxidative Phosphorylation 
3.1.2 Mitochondrial Genetics 
Mitochondrial DNA is a double-stranded circular genome of 37 genes encoding 13 proteins, 22 
transfer RNAs, and two ribosomal RNAs that play a role in formation of the respiratory complexes 
I, III, IV, or V.7; 8 
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Figure 2. Mitochondrial DNA Map ©9 
Each mitochondrion has multiple copies of mtDNA. There is typically only one type of mtDNA 
found in individuals without mitochondrial disease. However, in some cases, such as those of 
mitochondrial disease, there may be different forms of mtDNA within a cell. This is known as 
heteroplasmy. Some of the mitochondria within the cell may contain normal mtDNA while others 
may contain mutant mtDNA. 
Mitochondrial DNA is transmitted from one generation to the next through the mother. 
This is called mitochondrial, or maternal, inheritance. Sperm cells contain little or no cytoplasm, 
which is where the mitochondria reside in cells. Thus they do not transfer mitochondria to the 
offspring. Alternatively, egg cells contain considerable cytoplasm and cytoplasmic organelles. As 
egg cell cytoplasm is sequestered from the progenitor germ cell, multiple and different copies of 
mtDNA, if present, are randomly apportioned to the egg cell. Thus, the heteroplasmy present in 
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the progenitor cells may be variably represented in the next generation. While a single cell can be 
heteroplasmic, so can an individual. Cells in an individual who carries mutant mtDNA may have 
variable amounts of mutant DNA, creating heteroplasmy. An individual who carries mitochondria 
with relatively few mutant mtDNA may not exhibit features associated with the corresponding 
condition. Whether or not one shows clinical features associated with a mitochondrial mutation is 
dependent on the mutational load, which refers to the amount of mutant mtDNA present. In order 
to show a disease phenotype, one’s mutational load must exceed a threshold in a particular tissue. 
This concept is known as the threshold effect, which states that accumulation of mutations does 
not result in phenotypic changes until a cell’s capacity to suppress mutation expression, or 
threshold, is crossed. This threshold is different for different tissues, meaning a particular 
mutational load may result in no or little phenotypic effect in one tissue, while causing disease 
features in another. 
3.1.3 Mitochondrial Disease 
While ATP production through OXPHOS is a prominent function of mitochondria, they also 
support other biochemical activities including the production and subsequent detoxification of 
reactive oxygen species (ROS), regulation of calcium signaling, and initiation of apoptosis.10 
Dysfunction of any of these myriad tasks can present as clinical disease. Mitochondrial disease 
can be caused by a mutation in nuclear DNA (nDNA) or mtDNA. Mitochondrial DNA is 
particularly susceptible to accumulation of mutations through oxidative stress, polymerase 
dysfunction, and exogenous toxins.11 Since mitochondria have fewer DNA repair mechanisms than 
the nucleus, mtDNA is more prone to the accumulation and propagation of mutations. 
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Different tissues of the body have different energetic needs based on function, and these 
needs typically correlate with the number of mitochondria in that tissue. For example, a neuron 
that is constantly firing requires a greater amount of energy than a skin cell. The brain uses 20 
percent of the body’s energy while comprising only two percent of the total body weight.5 Cells 
containing more mitochondria will be more susceptible to dysfunction with a lower mutation load. 
This is a part of what results in the clinical variability of mitochondrial disorders, as the mutation 
load in a particular tissue will dictate if and which symptoms arise in an individual’s clinical 
disease course. 
Mitochondrial respiratory chain defects (often referred to simply as “mitochondrial 
disease”) affect approximately 12.48 in 10,000 individuals world-wide.12 These conditions vary 
widely in presentation. Age of onset can vary from infancy to adulthood depending on the 
condition, and there are multiple clinical features variably associated with mitochondrial disease.11 
These features include myopathy, seizures, low energy, muscle weakness, and ragged red fibers 
as determined by a histological studies of a muscle biopsy specimen. The specific combination of 
these features leads to a suspected clinical diagnosis of a specific mitochondrial disease. 
3.2 MITOCHONDRIAL ENCEPHALOMYOPATHY, LACTIC ACIDOSIS, AND 
STROKE-LIKE EPISODES – MELAS 
Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) is a multi-
system mitochondrial disorder. Although the exact incidence of MELAS is unknown, in part 
because of its variability of clinical presentation, and it is a rare condition, it is the most common 
of the mitochondrially-inherited disorders.13 
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3.2.1 Molecular Basis 
MELAS is caused by mutations in the mtDNA. The most common cause of MELAS, implicated 
in 80% of MELAS cases, is a m.3243A>G mutation in the MT-TL1 gene, first described by Goto 
et al in 1990. This mutation prevalence is estimated to be 0.06%, or 60 in 100,000 individuals in 
the general population.13 This mutation is known to cause dysfunction of tRNALeu(URR).14 There 
are at least 28 other mtDNA mutations and at least seven mitochondrial tRNA gene mutations that 
have been identified as leading to MELAS, including MT-ND1, MT-CO3, MT-ND4, MT-ND6, and 
MT-CYB. 13; 15; 16 
Figure 3. Pathogenic Mutations in tRNALeu(UUR) © 17 
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3.2.2 Clinical Manifestations 
The age of onset, clinical features, and severity of MELAS differ significantly among affected 
individuals due to cellular heteroplasmy and differences in the threshold effect in different tissues. 
While all individuals with MELAS carry the mutation from birth, few affected individuals show 
symptoms early on. In fact, a distinguishing feature of MELAS is that affected individuals 
typically do not show symptoms from birth; rather, they typically have normal birth and early 
development. This is likely due because energy output at that time is enough to meet the body’s 
energy requirements. Symptoms do not begin to manifest until the demands of the body exceed 
the mitochondrial energy output.13 The range of age of onset of symptoms is most commonly 2-
40 years old, but usually individuals with MELAS begin to present with symptoms in childhood, 
between the ages of five and 15 years-old.13; 15  
There are six core features of MELAS that are present in 90% of cases: (1) age of onset of 
symptoms at less than 40 years old; (2) encephalopathy, frequency appearing as seizures, 
dementia, or both; (3) exercise intolerance; (4) lactic acidosis; (5) ragged red fibers on muscle 
biopsy; and (6) stroke-like episodes (before age 40 years). There are three additional features 
commonly identified, two of which are typically required to make a diagnosis. These features are 
normal early development, recurrent headaches, and recurrent vomiting.11; 13; 16; 18 Additional 
features of MELAS affect several body systems. Neurological features associated with MELAS, 
in order of likelihood of occurrence include hemiparesis, hearing loss, hemianopsia, learning 
disabilities, basal ganglia calcification, myoclonus, cerebellar signs, memory impairment and 
episodic comas. Ophthalmologic symptoms include external opthalmoplegia, optic atrophy, and 
pigmentary retinopathy. Cardiovascular symptoms seen in patients with MELAS include 
cardiomyopathy, chronic heart failure, pulmonary hypertension, and angiopathy. Endocrine 
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symptoms include diabetes mellitus and growth failure, while gastrointestinal symptoms include 
abdominal discomfort, constipation, or pseudo-obstruction. Nephropathy and vitiligo are other 
symptoms of MELAS include.11; 13 
3.2.3 Diagnosis 
Mitochondrial disease is often difficult to recognize clinically because the features overlap many 
other conditions. However, once suspected, a diagnosis can be confirmed with biochemical and 
molecular testing. Biochemical testing including blood lactate and pyruvate levels, urine organic 
acids, blood amino acid levels, and muscle respiratory chain enzyme analysis may lead to a 
suspicion of MELAS, but molecular testing is ultimately necessary to confirm it. Molecular testing 
includes allele specific techniques and full mitochondrial chromosomal sequencing. Due to 
heteroplasmy, it is possible for one tissue type, such as blood, to test negative for the mutation, 
while another tissue, such as muscle, tests positive; thus analysis of multiple tissues may be 
necessary. The challenges with diagnosing MELAS often result in diagnosis being a multi-step 
process. This process could require multiple visits to one or more health care providers, which may 
pose additional challenges to diagnosis of MELAS in populations without affordable access to 
advanced healthcare. 
3.2.3.1 Sample Specifications 
Research has been conducted to determine which sample type is most suitable for providing the 
best possible reflection of heteroplasmy in an individual.19 Because it is known that different 
tissues will show different levels of heteroplasmy, it may be best to find the most clinically affected 
tissues in order to have the highest likelihood of identifying abnormal mtDNA. One study 
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compared five tissue types including blood leukocytes, skin fibroblasts, hair roots, urinary 
sediment, and cheek mucosa to determine which provided the best estimate of mutational load.19 
Molecular testing of skeletal muscle has long been considered the gold standard of molecular 
diagnosis, but this may no longer be the case when looking for an initial diagnosis in patients.20 
Testing blood is a less invasive sample type for testing; however, while the m.3243A>G mutation 
is detectable in blood, the mutational load will deteriorate over time in blood leukocytes.20 In some 
cases, testing for this mutation in blood in a severely clinically affected individual reveal continued 
reduction of mutational load with aging, and results can even be negative.19 Thus, when 
considering testing for asymptomatic individuals, it is paramount to use something other than a 
blood sample in order to reduce the likelihood of returning a false negative result. One study 
showed that buccal mucosa and urinary sediment were the best non-invasive tissue types to test, 
as both samples provided for mutation detection in cases when blood samples did not.19  Several 
studies have also supported the use of urinary epithelial tissue for primary diagnosis when trying 
to use a non-invasive sample collection method.19-21 
3.2.4 Management & Treatment 
Treatment of MELAS is two-fold. First, supportive care must be based on the symptoms in the 
affected individual.11 Patients should be monitored for progression of their condition and for 
development of new symptoms through routine evaluation by ophthalmology, cardiology, 
endocrinology, and neurology. Second, some medications may be of some benefit in mediating 
the cellular damage caused by the underlying energy defect. There are no consensus guidelines for 
specific drug regimens for MELAS patients.13 Biochemical treatment plans for mitochondrial 
diseases, including MELAS, include an array of nutritional supplements, vitamins, and cofactors 
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of uncertain efficacy.16 Currently, these treatments include agents such as coenzyme Q10 (CoQ10), 
L-arginine, B vitamins, idebenone, creatinine, and levocarnitine. These treatments aim to minimize 
the demands of mitochondria and maximize their function by augmenting the production or 
utilization of ATP and reducing the effects of excess production of reactive oxygen species.13  
CoQ10 is the most commonly used agent to treat patients with mitochondrial disorders due to the 
key role of Co-enzyme Q as an electron acceptor within respiratory chain complex III. Results of 
CoQ10 use in the treatment of MELAS have been mixed, and it has not resulted in sustained clinical 
benefit even though it appears to improve some biochemical markers of MELAS.13 L-arginine is 
another commonly used agent in MELAS treatment regimens. It is proposed to play a role in 
reducing the frequency of stroke-like episodes in individuals with MELAS due to its role in nitric 
oxide metabolism, and several studies have shown its utility for this purpose.13; 22-24 However, its 
true efficacy remains controversial. L-carnitine and idebenone have been used as antioxidants, but 
the latter has fallen out of favor more recently. Creatinine is a high energy phosphate compound 
that becomes depleted in muscles of patients with respiratory chain defects.25 However, controlled 
studies of its use have given mixed results on efficacy. Overall, when designing a drug therapy 
regimen for a patient with MELAS, clinicians must balance the potential benefits of particular 
treatments with the risk for adverse reactions, financial burden to the patient, the patient’s 
symptoms, and other individualized health factors.13 
 Other treatments aimed at reducing effects of MELAS include non-drug therapies, or 
lifestyle modifications including diet and exercise programs. In particular, the effects of exercise 
and training in patients with mitochondrial disorders have been examined.26-31 These few studies 
suggest that there are deleterious effects of limited physical activity because they perpetuate the 
mitochondria’s oxidative impairment. In contrast, endurance training appears to improve 
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mitochondrial function in vitro and overall muscle strength in vivo.26; 29; 31 The mechanism for this 
improvement may include inducing “gene shifting,” a process by which the molecular events 
leading to expression of metabolic myopathy are reversed.32 As understanding of the pathways 
involved in mitochondrial functions are elucidated, perhaps the development of more regimented 
treatment and management plans for patients with MELAS will occur. However, it has been 
proposed that the most promising treatments lie not in pharmacological therapies but in developing 
gene therapies aimed at manipulating heteroplasmic mtDNA genotypes in favor of wild-type 
mtDNA.33 
3.3 THE AMISH 
The Amish are a group of people with converging beliefs regarding religion, society, and plain 
living. They are known as the Plain Community, believing in plain living as a part of their religious 
beliefs. 
3.3.1 Amish Culture 
The Amish community arose as the result of a split in religious views that occurred in the Protestant 
Reformation in Europe. Anabaptists, who believed that Baptism should occur later in life as an 
intentional act by an informed adult, ultimately established the Anabaptist church.34 Later, there 
was a further separation of the Anabaptists into the Mennonites and Amish based on treatment of 
individuals excommunicated from the church, with the Amish being followers of Jakob Ammann, 
who believed in stricter adherence to excommunication laws.35 
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Throughout the early 16th to the mid-17th centuries, there was a migration of the Old Order 
Amish from Europe to America in pursuit of freedom from religious persecution. Today the Amish 
living in the United States are clustered in about 200 settlements across the country.35 A 2010 
report showed that the highest populations of Amish in the United States were located in Ohio, 
Pennsylvania, and Indiana (Figure 4).36 While the foundation of each of these communities is 
rooted in the same history, there are slightly divergent beliefs among the different settlements, just 
as there were between the Mennonites and the Amish. The foundation of Amish culture is plain 
living, which is a way of life that rejects modern conveniences and technologies whenever 
possible. They believe in making choices that are best for the community, and they separate 
themselves from popular culture. Religion is at the core of the values by which the Amish live 
their lives.  
 
Figure 4. Number of Amish Adherents by State, 2010©36 
 
The Amish believe that, “true grace can only be achieved if one lives in isolation from the 
non-Amish world.” 35 This separates them from some laws governing other United States citizens. 
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In order to maintain their separation from the non-Amish, or “English” world, the Amish depend 
on one another and their community to provide assistance when self-reliance is not possible. 
3.3.2 Amish Medical Beliefs 
The combination of the core Amish beliefs and their desire to avoid use of modern conveniences 
and technologies once led to the belief that seeking health care outside of the Amish community 
was unacceptable. However, over time many settlements have come to accept the life-saving 
qualities modern medicine has to offer. This facet of Amish culture is exemplified in cases where 
the Amish must seek English medical care for their children. In many of these cases, a single 
family is often unable to cover the cost of all expenses related to this care, so the community 
contributes whatever additional funds are required to help the family afford the care their child 
needs. This practice has developed because the Amish beliefs in self-reliance, commitment to 
community aid, and belief that God’s will is supreme limit their participation in traditional or 
government-subsidized health insurance. Due to the ever-rising costs of health care in the United 
States, the Amish’s reliance on English healthcare has been difficult for many communities. As a 
result, the Amish Hospital Aid Fund has been growing since the 1960s and serves as a source of 
communal monies to be put toward the healthcare of those who are unable to bear the entire 
financial burden associated with seeking healthcare.35 
3.3.3 The Amish and Genetics 
Over time, an increased frequency of specific autosomal recessive (AR) conditions has been 
recognized in Amish people due to founder effects, resulting from a “genetic bottleneck,” seen 
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when a small group of founders immigrate to a new location. In a self-isolating community such 
as the Amish, this results in the gene pool being much more limited than in larger or more 
geographically and ethnically diverse populations. In this situation, any autosomal recessive 
mutation in a founder individual will result in an increased prevalence of that mutation in 
subsequent generations in the community due to inbreeding. While the overall rate of genetic 
disease in the Amish is similar to the general population, its spectrum is different. There is an 
increased incidence of numerous autosomal recessive conditions, for example glutaric acidemia 
and propionic academia, in some Amish settlements. There is limited evidence of mitochondrial 
disorders in Amish populations; prior to recent diagnoses made in Western Pennsylvania by this 
principle investigator and colleagues, mitochondrial disease in the Amish had been unrecognized. 
This discovery of a mitochondrial condition in the Amish is significant for three reasons: the family 
sizes often found in Amish communities result in risk to a significant number of individuals; the 
potential for significant morbidity related to these conditions; and the potential for benefits from 
early recognition and intervention. 
3.4 SELF-ADMINISTERED QUESTIONNAIRES AS A MEASURING TOOL 
Questionnaires have long been used as a method for eliciting information from research subjects. 
When trying to elicit information about knowledge gained through an educational intervention, a 
pre- and post-educational intervention, or a “before and after” model, has commonly been used. 
Many studies have shown the efficacy of utilizing self-administered questionnaires for this purpose 
in different study populations. Most commonly, this model is used in a school setting to determine 
if students are gaining the knowledge associated with learning objectives.37; 38 Questionnaires can 
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only provide useful information in research when they are properly designed and administered.39 
Many factors can affect whether questionnaire responses provide the desired information to further 
research goals.  Good formatting is paramount in effectively utilizing a questionnaire as a 
measuring tool because a well-formatted questionnaire can reduce measurement error and increase 
response rates.40 This includes word choices and order of questions, the placement of instructions, 
the layout of the questions, the length of questionnaire, the response categories, the cover page, 
and many other features. All of these can work to provide better measurement outcomes.40 When 
determining formatting, the primary focus is the audience, or respondents. Concentrating attention 
on the specific needs of respondents will help guide choices related to the aforementioned 
questionnaire features. For example, when measuring knowledge using questionnaires, it is 
important to place knowledge questions before attitude questions.39 Asking respondents if they are 
familiar with or aware of a concept before moving forward to gain deeper insight into their 
understanding or attitudes toward that subject may provide a more accurate representation of their 
true level of knowledge regarding that concept. Another factor that may play a role in questionnaire 
administration is the physical format of the questionnaire. For example, when administering 
questionnaires to the general population, a personal electronic device might be the easiest 
questionnaire method, but in the Amish community, this is not an option. Rather a booklet format 
was selected because this was thought to be a format with which they might be most familiar.  
3.4.1 Use of Questionnaires in Amish Communities 
In the Amish and other communities, there are several factors to be considered when administering 
questionnaires. A key consideration is the level of comprehension by the respondent based on 
factors such as reading level and prior exposure to questionnaire content. Formal schooling in this 
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community generally ends after the eighth grade. When administering questionnaires to the Amish 
population, modifications must be made to ensure the comprehension of the respondents in order 
to obtain the most accurate representation of respondent data. Modifications made include 
targeting the reading level to sixth to eighth grade, as is recommended for general population 
studies, and altering word choice to exclude words with culturally-inappropriate connotations or 
that make referral to technologically-advanced ideas. Some studies have suggested that personal 
interviews may be beneficial to ensuring this comprehension. However, these and other studies 
have also found that answers given in personal interviews may differ from those provided on self-
administered questionnaires.41 Overall, there is limited research conducted in this population to 
determine the best means of assessing knowledge gained from an intervention to conclude that 
self-administered questionnaires would provide a more accurate representation of knowledge than 
personal interviews.  
3.4.2 Skip Patterns 
A skip pattern is a questionnaire tool used to allow respondents to skip one or more questions 
based upon their selected answer to a particular question, called the directive question rather than 
being required to answer every question.42 Well-designed skip patterns allow a respondent to easily 
identify the next question he or she should answer based on their answer to the directive question. 
When utilized visually or in basic language, skip patterns can aid respondents who have lower 
reading levels.42 However, skip pattern development is a nuanced process that benefits from 
extensive pre-testing, preferably by a member of the population being surveyed, to be most 
effective.42 There are several forms of skip patterns, all with the same goal: trying to reduce errors 
of both commission, the tendency not to skip a question when directed to do so, and of omission, 
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the tendency to skip questions when not directed to do so.43; 44 Most commonly, visual skip patterns 
can be utilized to provide the highest level of compliance.42-44 
3.5 HIGH-RESOLUTION MELT PROFILING 
High-resolution melt (HRM) profiling is a process by which sequence variants can be identified 
through the exploitation of thermal denaturation of nucleic acids.45 Denaturation of DNA 
containing more G-C base pairs occurs at a higher temperature than that of DNA containing more 
A-T base pairs due to the extra hydrogen bond in a G-C base pair. The HRM profiling process was 
first described in 2003 by Wittwer et al.45-47 In this method, the region of interest is amplified 
through real-time PCR, then the double-stranded PCR product, or amplicon, is denatured in an 
HRM-capable real-time PCR machine. The denaturing process is monitored closely using 
intercalating dyes, which fluoresce brightly when bound to double-stranded DNA (dsDNA) but 
lose their fluorescence as the dsDNA denatures in single-stranded DNA (ssDNA). The result is 
the generation of a post-PCR melt profile of the sample, which can be compared to that of a sample 
containing a known genetic sequence to determine the presence of a sequence variation.45-47  
3.5.1 High-Resolution Melt Profiling in mtDNA 
HRM profiling using amplicon-based genotyping has proven to be sensitive enough to identify 
some mtDNA point mutations, including the m.3243A>G MELAS mutation, at a heteroplasmy 
level at or below 10%.47 In this method, the melt profiles of test samples are compared to those of 
control samples. Comparison controls are comprised of samples of the mtDNA reference 
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sequence, samples homoplasmic for the mutation of interest, and samples made by diluting the 
homoplasmic mutant mtDNA, resulting in samples with different levels heteroplasmy for the 
mutation of interest. These are used to define standard melt profiles for comparison with the test 
sample. If the dilutions used for comparison are specific enough, HRM can provide resulting 
heteroplasmy levels ±1%.47 
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4.0  SIGNIFICANCE 
4.1 PUBLIC HEALTH AND MITOCHONDRIAL DISEASE 
Over the past several decades, research has shown that mitochondrial respiratory chain deficiency 
is one of the most prevalent classes of genetic disorders. The minimum prevalence of 
mitochondrial disease caused by either nDNA or mtDNA mutations has been estimated to be 
approximately 1 in 5,000 individuals world-wide.48 As described previously, mitochondrial 
diseases are characterized by phenotypic and genetic heterogeneity and frequent multisystem 
involvement.49 Primarily because of the phenotypic heterogeneity, it is often difficult to identify a 
mitochondrial disease. There are many different symptoms that can arise with mitochondrial 
disease. However, many of these symptoms can be seen in isolation in the general population in 
those who do not have mitochondrial disease.  Many individuals who suffer from mitochondrial 
disease are misdiagnosed with other conditions.12 These may include atypical cerebral palsy, 
various seizure disorders, and other childhood or age-related diseases. In other cases, a pattern of 
symptoms may not have been recognized, and an individual may carry multiple complex disease 
diagnoses without a caretaker having recognized their relatedness.12 For example, an individual 
may have a diagnosis of insulin-dependent diabetes mellitus and suffer from hearing loss. While 
it is possible these two diagnoses are unrelated, they can also be seen in combination in patients 
with the common MELAS mutation. It is only when a caretaker recognizes the pattern of 
symptoms in an individual or a family as being related that diagnosis of a mitochondrial disorder 
is considered.  
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Even in cases when mitochondrial disease is suspected, it may be difficult to confirm a 
diagnosis due to an inability to identify a specific respiratory chain defect or an inability to detect 
a genetic mutation leading to disease. In many cases, mutations and defects can escape 
identification using blood, saliva, or urine sediment testing. While a muscle biopsy has long been 
considered the gold standard in mitochondrial disease diagnosis, sometimes diagnosis requires 
multiple biopsies. Due to the invasiveness of this procedure, the landscape is shifting in favor of 
genetic testing as a gold standard of diagnosis. However, this mechanism can also encounter 
difficulty due to variable detection of mutations in different tissue types. This long process of 
diagnosis can leave patients and caregivers frustrated and ultimately result in an undiagnosed 
patient due in part to testing fatigue or limited financial resources to pursue additional testing. 
Providing education regarding MELAS and other mitochondrial diseases to members of 
the general population and health care providers could help promote recognition of mitochondrial 
disease in individuals and families. In 2004, the Surgeon General’s Office launched the Family 
Health History Initiative, which was an effort to promote awareness and improve family health 
history ascertainment and utilization in order to better identify individuals at risk for diseases and 
disorders based on family history.50; 51 While this effort has been geared primarily toward complex 
diseases such as heart disease and diabetes, this initiative could also be used to help families 
identify symptoms related to mitochondrial disease in order to help healthcare professionals 
identify patterns in families. It is especially important to promote this discussion among families 
because research has shown, at least historically, that many primary care physicians were not 
eliciting adequate family histories for identification of familial or hereditary conditions.52 
Obtaining family health history can be combined with increased efforts to promote education about 
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mitochondrial disease to help increase the number of affected individuals and families who are 
being diagnosed and treated accordingly.  
Increased diagnosis might promote increased demand for additional research into treatment 
and management options for individuals affected with mitochondrial conditions. Diagnosis and 
proper treatment may help to decrease the financial burden on society and the public healthcare 
system that is associated with undiagnosed individuals where symptom-based treatments can 
improve long-term outcomes. 
4.2 THE IMPACT OF MELAS 
Because of the variable presentation of MELAS and the sometimes cumbersome diagnostic 
process, those who have this condition may not be recognized and diagnosed for many years.53 
This means that individuals affected with the condition often do not get appropriate care to 
maintain their best possible quality of life, and women who are mildly, or even moderately, 
affected may not understand that they are at risk to pass the condition to their offspring.16 
MELAS has a broad spectrum of possible clinical features with variable severity. When 
MELAS is expressed in its most severe form, it is a debilitating condition, and patients required 
detailed attention and medical care to maintain a reasonable quality of life. Treating each feature 
of the condition without understanding the way the symptoms are connected to an underlying 
comprehensive diagnosis may leave gaps in care for individuals with MELAS. 
While there is limited data on the subject, it is likely that one of the best ways to ensure the 
highest quality of life and best treatment or management possible is to identify MELAS as early 
as possible. Early diagnosis of MELAS allows for prevention or faster treatment of neurological 
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symptoms. For example, identification of the condition would make parents and physicians aware 
of the potential for seizures and stroke-like episodes before a child experiences those symptoms. 
Another example would be screening for hearing loss and diabetes since those are commonly 
related symptoms. Specifically in regards to diabetes, there is evidence that earlier detection and 
treatment may lead to better outcomes.54 The benefits of prevention or better control of these and 
other symptoms resulting from early diagnosis may truly impact an affected individual’s future.12; 
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4.3 AMISH HEALTH CARE 
Dr. D. Holmes Morton and Caroline Morton established The Clinic for Special Children in 1989 
to provide care to the children with genetic disorders in the Pennsylvania Amish and Mennonite 
communities. The work of this clinic dramatically demonstrates the impact of simple 
improvements in care and early detection of disease. In addition, parental and community 
education have been shown to change the course of a child’s disease and life. One example of this 
impact is the discovery of glutaric acidemia, type 1 as the cause of what was once called “Amish 
cerebral palsy” in 16 Amish children who had common ancestors, or one “founding” couple. 
Children found to have this condition through early screening live healthier lives as a result of 
comprehensive follow-up care.34 
The lifestyle of the Amish is one that does not easily allow them to spend large amounts of 
money on traditional health care. In 2010, a $1.5 million operating budget allowed the clinic to 
provide care that saved the community an estimated $20 to $25 million in caring for their children 
with autosomal recessive conditions.2 For example, there has been a 94% decrease in hospital costs 
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associated with maple syrup urine disease (MSUD), saving at least $4.3 million in annual health 
care costs for the Lancaster County Amish community.2 If this same paradigm is applicable to the 
lives and care of individuals with mitochondrial disease, it may result in a significant impact on 
the affected families in the Amish community. Since the Amish are such a communal group, 
positively impacting just a few families will in turn positively impact the community as a whole. 
Given the recent identification of a family in the Mercer County Amish community with 
the common MELAS mutation, along with the large family sizes in traditional Amish 
communities, it is hypothesized that there will be a significant number of members of the 
community who have some degree of symptomatology related to undiagnosed MELAS. According 
to clinicians at The Clinic for Special Children who serve the Lancaster County Amish 
communities, as many as 50% of patients in their community with chronic disease remain without 
a specific diagnosis.1 Assessment of appropriate individuals from this and related populations for 
MELAS and other mitochondrial disorders may lead to provision of targeted medical care for 
them. 
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5.0  MATERIALS AND METHODS 
The study was designed to determine the frequency of MELAS in the Mercer County Amish 
community, to provide an investigator-designed educational program to community members who 
may be affected or know individuals who are affected by MELAS, to study the effectiveness of 
the educational session, and to construct an extended family pedigree of the index family. This 
research protocol was submitted to the University of Pittsburgh’s Institutional Review Board (IRB) 
and was approved on November 13, 2014 (Appendix A).  
5.1 RECRUITMENT PROCEDURES 
Assessment of family interest in participation in a research study of MELAS in the Amish 
community was completed through outreach to the index family that is followed clinically at the 
Children’s Hospital of Pittsburgh of UPMC by the primary investigator and a co-investigator. A 
letter was sent to the family asking them to contact the primary investigator if they were interested 
in learning about the study (Appendix B). A conversation was then arranged to briefly explain the 
goals and plans of the proposed research and to see if the family was interested in participating. 
Since the family was interested, per local customs, they were asked to arrange for communication 
between the study team and the local Deacon. The Deacon granted permission to conduct research 
in the community (Appendix C). 
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The family then confirmed that they would organize a meeting at their home to facilitate 
the study activities. The index family invited their extended family members to attend the first 
study visit. This extended family was primarily composed of maternal family members. 
5.2 STUDY VISIT ONE 
5.2.1 Pre-Education Questionnaires 
After introductions of the study staff in attendance and a brief explanation of the research study’s 
aims and activities, participants were informed that they had the option to either continue or decline 
further participation in the study. At this point, a pre-education questionnaire (Appendix D) was 
distributed. The purpose of this questionnaire was to gauge each study participant’s understanding 
of and exposure to information about genetics, mitochondrial disease, and MELAS prior to the 
study’s start. Questionnaires were distributed in a manila envelope to all individuals willing to 
participate and over the age of 14 years. Each manila envelope was labeled with a code, and each 
envelope contained both a pre-education questionnaire and a post-education questionnaire. Each 
questionnaire was also coded to allow for pre- and post-education questionnaires to be compared 
while maintaining anonymity. After taking the pre-education questionnaire, participants retained 
their manila envelope until later in the session. Those who did not want to participate were able to 
decline participation by returning the questionnaire without answers.  
Investigators were able to administer the pre-education questionnaire prior to obtaining 
written informed consent. This was permissible because the IRB provided approval for a “waiver 
for written consent” for completing the pre-education questionnaire. This waiver can be seen 
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within the approval for the research study, which is shown in Appendix A. This “waiver for written 
consent” was requested for this study activity because investigators were concerned that the 
informed consent process would bias responses to the questionnaire because the informed consent 
document contained information describing the topics queried in the pre-education questionnaire. 
5.2.1.1 Questionnaire Construction 
The questionnaire was composed of 16 multiple-choice questions, which were divided into four 
sections. The first section contained questions about basic genetics, and the second contained 
questions about autosomal recessive genetic disease. The third section contained questions about 
mitochondrial disease, and the fourth contained questions about MELAS specifically. 
A skip pattern was utilized to allow participants to skip any of the four sections if they did 
not have prior knowledge of the topic covered in that section. This was achieved by using the first 
question in each section to ask a fundamental question related to the topic in that section and 
making one of the multiple choice answers, “I have never heard of [topic].” If a participant chose 
this option, it directed the participant to skip the remainder of that section and move to the next 
one. Each question also had the multiple-choice answer: “I am unsure of the correct answer.” This 
option was offered in an attempt to mitigate skewing of results due to random guessing. 
Finally, at the end of the questionnaire, there was a section to be completed only by 
participants who had or knew someone who had a mitochondrial disease. This final section 
included several quality of life questions developed by modifying the Newcastle Mitochondrial 
Disease Scales.56 While approved for collection from this group of study participants, these data 
will be analyzed by team members in parallel with work for this study and are not reported here. 
This questionnaire was developed with the aid of Dr. Todd M. Bear, who directs the Office 
of Health Survey Research in the Institute for Evaluation Science, conducts numerous health 
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surveys yearly, and currently teaches the “Health Survey Methods” and “Measurement in Social 
and Behavioral Sciences” courses for the Graduate School of Public Health at the University of 
Pittsburgh. Additionally, this questionnaire was reviewed during a core educational conference for 
professional genetic counselors and genetic counseling students at the Children’s Hospital of 
Pittsburgh of UPMC, where these professionals were given the opportunity to provide feedback 
on the questionnaire. 
5.2.2 Informed Consent 
A comprehensive informed consent process was completed following the completion of the pre-
education questionnaires. The two informed consent documents to be used, adult (Appendix E) 
and pediatric (Appendix F), were approved on November 13, 2014. The components of the consent 
form were reviewed in a group with a co-investigator to answer questions and facilitate written 
informed consent for each subject. Adult subjects who were not mentally impaired were asked to 
consent to the study. Adults who were mentally impaired could assent to the study while their 
parents were asked to provide consent. Children over the age of 14 were also asked to assent to 
the study while their parents and the parents of children under the age of 14 years were asked to 
consent for study participation.  
Subjects and parents/guardians were informed that their participation and their child’s 
participation were completely voluntary, and their decision to participate in the study would not 
impact the clinical care of themselves or their child at UPMC facilities. The informed consent form 
included consent for the following: 
 An educational intervention
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 Pre- and post-educational questionnaires for comparison and assessment of efficacy
of the educational intervention 
 Blood, urine, and buccal samples for analysis of the m.3243A>G mutation in the
MT-TL1 gene 
 One-on-one session to elicit individual and family medical history
 Release of medical information from UPMC and other facilities
 Genetic counseling for genetic test results
The subjects were given as much time as necessary to consider whether or not they would 
like to participate in research while the primary or co-investigators were available to address any 
questions or concerns they had. Those who did not want to participate retained their pre-education 
questionnaires. If an individual chose to consent to the study, he or she signed and returned the 
consent form. If an individual chose not to consent to the study, he or she was encouraged to remain 
for the group educational session that followed the consent process, but was not included in the 
remaining study activities. This allowed community members who did not want to participate in 
research the opportunity to learn valuable information about this condition due to its potential 
implications for them, their families, and their community. 
5.2.3 Educational Intervention 
The educational intervention was done following the informed consent process. The intervention 
was an educational session with verbal and visual components that was designed to provide 
participants with information about MELAS and mitochondrial disease. The session included 
information about the following: 
 mitochondria
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 different modes of inheritance for genetic diseases
 mitochondrial DNA
 the meaning and involvement of heteroplasmy and mutational loads
 mitochondrial inheritance and its relationship to MELAS and the participants’ community
 information about the common MELAS mutation and its related phenotype
 the basic clinical features of MELAS
 the treatment and management options for patients with MELAS
5.2.3.1 The Presentation 
The educational intervention was presented verbally by this co-investigator using a visual aid 
handout (Appendix G) developed by this co-investigator with input from the study team and others 
including genetic counselors at the Children’s Hospital of Pittsburgh and faculty members in the 
Department of Human Genetics in the Graduate School of Public Health at the University of 
Pittsburgh. Clarification was provided per participant questions and feedback. 
The presentation was designed to be interactive, similar to a genetic counseling session, in 
order to assess the understanding of participants throughout the presentation. This design allowed 
for minor adjustments to be made in the way information was being presented based on this 
investigator’s perception of participant understanding. This would be similar to a genetic counselor 
making adjustments in a genetic counseling session based on his or her assessment of a patient’s 
level of understanding.57 For example, changing the language used when discussing a particular 
topic may provide an opportunity for better participant comprehension, and the need to do so may 
be based on an assessment of facial expressions, body language, or participant verbalizing of lack 
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of understanding, all of which can be assessed using an interactive educational intervention. The 
presentation also allowed for additional time for questions.  
5.2.4 Post-Education Questionnaires 
A post-education questionnaire (Appendix H) was administered following the educational session. 
This questionnaire was nearly identical to the pre-education questionnaire except for the quality 
of life questions and acknowledgment of participation at the end. All participants were given time 
to complete the questionnaire prior to individually moving forward with additional study activities. 
After completing the post-education questionnaire, participants were asked to return their manila 
envelope containing both their pre- and post-education questionnaire to a study staff member. The 
staff member confirmed the presence of both questionnaires before accepting each envelope.  
5.2.5 One-on-One Interview Sessions 
Following the educational intervention and post-session questionnaires, one-on-one interviews 
were conducted between either the primary or a co-investigator and a family historian. This 
typically included either an individual study participant or a nuclear family of participants. The 
first activity completed in each one-on-one interview was privately and confidentially to confirm 
informed consent and willingness to participate in the study. This was done to ensure that no 
participant was participating unwillingly due to a sense of social obligation or pressure that may 
have arisen due to the group setting or the participants’ intrinsic sense of community. 
The purpose of the interview was to collect a detailed family and medical history from all 
participants. Using a list of clinical features associated with MELAS and mitochondrial disease 
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(Appendix I), each historian was asked to identify any features associated with mitochondrial 
disease in themselves or their family members. This list was used by investigators to ensure 
uniformity in recording information since sessions were conducted by different investigators. 
Each historian provided information that was to be used for construction of a pedigree of 
all individuals discussed during the session. The historian would answer questions about him- or 
herself, his or her immediate family, and the nuclear families of any extended family members not 
present at the study visit. Standard pedigree construction allows for collection of health 
information about family members which is regarded as hearsay; this means that the information 
has not been confirmed by the family member in question, and there is no clinical evidence present 
to support the information being recorded.58 Regarding each family member, the historian was 
asked whether he or she exhibited the symptoms of mitochondrial disease listed on the 
investigators’ checklist. 
During the one-on-one interviews, participants also signed medical release forms for 
records from facilities where the individual was seen for an issue that may be related to 
mitochondrial disease. 
5.2.6 Sample Collection 
Following the one-on-one interview session, each participant was asked to provide urine and blood 
samples. This collection was coordinated by study staff and completed by a medical doctor (MD) 
investigator. Blood samples were collected using lancets to pierce the finger and the blood drops 
were blotted onto newborn screening filter paper to store the sample. Urine was collected in urine 
cups privately by each participant without investigator oversight. All samples, both blood and 
urine, were labeled with the participants’ coded identification numbers. Filter papers were dried 
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before storing, and for traveling; urine samples were stored on ice in a cooler until they were 
transferred to the primary investigator’s laboratory freezer pending sample analysis. 
5.3 SAMPLE ANALYSIS 
DNA analysis of samples was conducted in the laboratory of the primary investigator under the 
supervision of the co-investigator Steven Dobrowolski, PhD at the Children’s Hospital of 
Pittsburgh by co-investigator Lina Ghaloul Gonzalez, MD. Samples were analyzed for the 
presence of the m.3243A>G mutation in the MT-TL1 gene using HRM profiling as described by 
Dobrowolski.47 HRM profiling identifies sequence variants by deviation in the shape of a post-
PCR melting profile performed in a 96-well formatted LightScanner96 instrument. Controls of 
100% A (wild type allele), 100% G (mutant allele), and defined mixtures of each were used to 
generate a standard curve for quantification of each allele in subject DNA.  
Briefly, participants’ DNA was extracted from dried blood spots and urine samples, and 
the mtDNA was amplified by a polymerase chain reaction (PCR) with validated primers.47 PCR 
was performed on each sample and on control DNA in duplicate in a 96-well plate. Then, using a 
96-well formatted LightSCanner96 instrument, a post-PCR melt profile was generated. Data were 
normalized, temperature-shifted, and converted to difference plots to allow for easier 
distinguishing of different genotypes by plotting the fluorescence differences between normalized 
and temperature-shifted curves as described.46 Melt calibration was performed using a single 
internal oligonucleotide calibrator.59 Analysis was performed with LightScanner software version 
2.0 Call-IT (v2.0.0.1131; Idaho Technology) using the melt calibration module. 
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5.3.1 High-Resolution Melt Profiling Method 
This method of sample analysis was chosen because of its cost efficiency, rapid turnaround time, 
and its previous utility in identifying the specific mutation of interest. This method was previously 
published by one of the co-investigators, which allowed for increased consultation and guidance 
regarding its use in this study. The co-investigator who performed the sample analysis practiced 
the method multiple times using volunteer samples for quality assurance purposes prior to 
performing study sample analysis. 
5.4 PEDIGREE CONSTRUCTION 
At the study visit, pedigree construction was initiated following the educational intervention, prior 
to the start of the one-on-one interview sessions. During this time, the primary and co-investigators 
asked the participants as a group to help identify and order family members of the index patients 
parents’ generation in order to save time and reduce repetitive information being taken during one-
on-one interviews. Progeny Clinical 6.0 software was used to construct a pedigree of this kinship. 
Study materials were saved in a private database behind the University of Pittsburgh firewall, 
accessible only with a password known to study staff. The first step of this pedigree construction 
was the creation of a database compatible with the requirements of data entry, after which the 
applicable data fields could be populated with information gathered in the one-on-one interview 
sessions. A legend was devised to depict the symptoms reported in individuals. This allowed for 
representation of the most commonly seen symptoms in the community. 
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5.5 QUESTIONNAIRE DATA ANALYSIS 
Questionnaire data was compiled and organized utilizing both Microsoft Excel and GraphPad’s 
QuickCalc software. Excel served as a repository for compilation and organization of data prior to 
inputting data into QuickCalc for statistical analysis, after which Excel was used to develop graphs 
of this analysis. 
Because the questionnaire data was paired and could be dichotomized, or put into two 
distinct categories, McNemar’s Test was the best tool to compare the differences in answers in the 
pre- and post-education questionnaires for statistical significance. Statistical significance and 
power of the results were determined based on the number of questionnaires completed by 
participants. 
5.6 STUDY VISIT TWO 
After completing sample analysis to determine the heteroplasmy level of all participants, a return 
visit was scheduled via letter to the index family on December 05, 2014 (Appendix J). After no 
communication was received in response to this first attempt at scheduling the visit, a second letter 
was sent to the family on January 9, 2015 (Appendix K). The patriarch of the index family then 
called but was unable to speak to the PI. During this phone call, the patriarch requested that rather 
than travel to Mercer County for a second visit, the study team mail individual sealed envelopes 
containing the results of each participant to the home of the index family for distribution to study 
participants at their next family gathering. Given the nature of this study, specific IRB approvals 
for the study, and the ethical concerns with distributing results of genetic testing without genetic 
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counseling, the PI sent a letter in response requesting that the index family and participants move 
forward with the results disclosure visit as previously planned (Appendix L). Given concerns about 
the burden of travel in winter weather on participants, the study team and index family opted to 
wait to disclose test results until March 2015.  
5.6.1 Results Disclosure Session 
The test results for each participant who had testing were disclosed by an MD, a licensed certified 
Genetic Counselor (CGC), or a supervised Masters of Genetic Counseling student. Results were 
disclosed to the participant who had testing along with supportive, patient-designated family 
members. For children who received results, the results were disclosed to the parent/guardian of 
the child in the child’s presence.  
To ensure consistency among all results disclosure sessions, before Study Visit Two an 
outline of information to be reviewed with participants was created to serve as a guide for the 
disclosure session (Appendix M). Results disclosure sessions were designed to follow the format 
of a traditional one-on-one genetic counseling session. Information to be provided included 
exploration of the subject’s recollections about mitochondrial inheritance and MELAS, a basic 
review of information regarding MELAS, the participant’s genetic test results, and a discussion of 
the implications of the results for the individual patients on their health and their children’s risks 
for health problems, including management options. During the disclosure visit, the psychosocial 
effects of the disclosure on the participants was further explored through questions and active 
listening.  
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5.6.1.1 Information Reviewed with All Participants 
Some information was reviewed briefly with all participants regardless of their test results. This 
information included a review of mitochondrial inheritance, with emphasis on maternal 
transmission of the mtDNA mutation to children and the lack of mitochondrial disease risk for 
children and grandchildren of men who had a positive test. The concepts of heteroplasmy and 
mutational loads were reviewed in the context of both likelihood of passing the mutation on to 
one’s children and for disease prognosis. The clinical features of MELAS and mitochondrial 
disease were also reviewed, with emphasis on the variability that can be seen in individuals due to 
heteroplasmy.  
5.6.1.2 Disclosing Negative Results 
For participants who had “No Heteroplasmy Detected” or “Negative” test results, after disclosing 
the result, study team members emphasized participant understanding of his or her result and the 
limits of the testing. In the case of such a negative result, this includes ensuring that the individual 
understands their extremely low likelihood of having children with the m.3243A>G mutation due 
to the mitochondrial inheritance pattern of the condition. This discussion was done based on the 
participant’s gender.  
5.6.1.3 Disclosing Positive Results 
For participants who had “Heteroplasmy Detected” or “Positive” test results, additional 
information was reviewed. The session included a review of the mitochondrial inheritance pattern, 
the clinical features of MELAS, the treatment and management options available to the participant, 
and next steps moving forward based on the participant’s heteroplasmy level.  
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5.6.2 Consenting Additional Study Participants 
At the time of Study Visit Two, investigators were prepared to consent additional participants for 
mutation studies and collect samples from them. These participants did not participate in the 
educational intervention or the associated questionnaires. These results are to be disclosed outside 
the scope of this project in the same manner as those disclosures included in this study. 
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6.0  RESULTS 
The first study visit occurred on November 15, 2014 in the home of the index family in Mercer 
County in Northwestern Pennsylvania (Figure 5).60 Study staff travelled to this location for all 
study-related activities that occurred for study visit one. This group included the primary 
investigator Jerry Vockley, MD, PhD; co-Investigators Amy Goldstein, MD; Lina Ghaloul 
Gonzalez, MD; Cate Walsh Vockley, MS, LCGC; this co-Investigator, and first year MS Genetic 
Counseling student Bess Wayburn, PhD. 
 
Figure 5. Mercer County, PA©60 
Approximately 35 individuals from four generations of the extended family of the index 
family attended this visit. After setting up all materials for the study activities, approximately 20 
individuals remained in the community space for the study staff’s presentation. Other family 
members moved to the main house with the children. This group of people was primarily composed 
of men, the majority of whom were the spouses of women who stayed for the study activities. 
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After a brief review of the study, 18 pre-education questionnaires were distributed. Two 
individuals chose not to participate prior to distribution of the questionnaires.  Approximately 20 
minutes were given to allow all participants time to complete the questionnaire to their satisfaction. 
The informed consent process was then led by Cate Walsh Vockley, MS, LCGC, with review of 
the informed consent forms in a group setting. She and primary investigator Dr. Jerry Vockley 
fielded questions about the study. Sixteen individuals signed consent forms to participate in the 
study; two of these 16 participants were parents signing for their children.  After collecting signed 
consent forms, the educational intervention commenced.  
6.1 EDUCATIONAL INTERVENTION 
The educational intervention information was presented verbally using visual aids. Each 
participant was given a color-printed copy of the educational handout in Appendix G. This co-
investigator presented information verbally while using the handout and participant feedback to 
present information. The presentation lasted approximately 20 minutes with additional time for 
questions, which were answered by the primary and co-investigators.  
After the educational intervention, post-education questionnaires were administered. This 
questionnaire was completed in a slightly different time-frame than the pre-education 
questionnaire because some participants chose to complete their questionnaires immediately, 
while others took breaks, and still others moved into one-on-one interview sessions with study 
staff members prior to completing the questionnaire. All participants were given ample time to 
complete the questionnaire and could ask questions at any point during the questionnaire if needed. 
Ultimately, 15 manila envelopes containing both pre- and post-education questionnaires were 
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collected. The three remaining questionnaires were not returned. One of these was from the 
original index patient, and two others were from other participants.  
Analysis of the data obtained from the questionnaires was completed after returning from 
the study visit. Two questionnaires, Q003 and Q007, were discarded from analysis. In both cases, 
the pre-education questionnaire was answered, but the post-education questionnaire had a note 
from the participant saying, “same [answers] as before.”  
The results of the questionnaires are shown in Table 1, which shows the complete set of 
answers given by participants for each questionnaire that was returned to the study team. 
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Table 1. Questionnaire Answers 
Question 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
Q002.1 S  S  S  S  S  S  S  0 S  S  0 0 1 0 0 S  
Q002.2 S  S  S  S  S  S  S  S  S  S  S  1 S  0 0 S  
Q003.1 1 1 0 1 0 0 1 1 IDK 1 0 1 1 0 1 0 
Q003.2 Wrote "Same [answer] as before" 
Q004.1 1 0 0 1 0 0 1 1 IDK 1 S  1 1 1 0 0 
Q004.2 1 1 1 1 0 0 1 0 1 1 0 0 1 0 1 0 
Q005.1 1 0 0 1 0 1 1 0 IDK IDK 0 0 0 1 1 0 
Q005.2 1 1 0 0 0 0 1 1 0 1 0 1 1 1 0 1 
Q006.1 1 0 0 0 0 0 0 1 IDK IDK 0 1 1 0 0 0 
Q006.2 1 0 0 0 0 0 0 1 0 IDK 0 1 1 1 0 1 
Q007.1 1 1 0 0 0 1 0 0 IDK 1 0 1 1 1 1 1 
Q007.2 Wrote "Same [answer] as before" 
Q008.1 IDK IDK IDK 1 IDK 1 0 0 1 0 1 1 0 0 0 0 
Q008.2 S  S  S  S  S  S  0 0 IDK 0 0 0 0 0 0 0 
Q010.1 1 1 1 0 0 0 0 1 IDK IDK 0 0 1 1 0 0 
Q010.2 S  S  S  S  S  S  0 0 IDK 1 0 1 1 1 1 1 
Q011.1 1 0 0 1 0 0 1 1 0 0 0 1 1 0 0 0 
Q011.2 1 0 0 0 0 0 0 1 0 IDK 0 1 1 0 1 1 
Q012.1 1 0 1 1 0 0 S  S  S  S  S  S  S  1 0 0 
Q012.2 1 0 0 0 0 0 1 1 IDK 0 0 1 1 1 1 1 
Q013.1 1 0 0 0 0 0 1 0 0 0 S 0 1 0 1 1 
Q013.2 1 1 1 1 0 0 1 0 1 1 1 1 1 1 1 0 
Q014.1 1 0 1 1 0 0 0 1 IDK 0 S 1 1 1 1 0 
Q014.2 1 0 0 0 1 1 0 1 IDK 0 0 1 1 1 1 1 
Q015.1 1 0 IDK IDK IDK IDK IDK 1 IDK IDK 0 1 1 1 0 0 
Q015.2 1 1 0 0 0 0 1 1 0 1 0 1 1 1 1 0 
1 = Correct Answer; 0 = Incorrect Answer; IDK = “I am uncertain of the correct answer”; S = Skipped question 
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Table 2. Pre-Education versus Post-Education Total Counts of Types of Answers 
Pre-Education Post-Education 
Total Number of  Correct answers 59 75 
Total Number of Incorrect 
Answers 
76 70 
Total Number of “Uncertain” 
Answers 
19 5 
Total Number of Skipped 
Questions 
22 25 
Total Number of Questions 
Answered 
154 151 
Total Number of Questions from 
Section #1 Correct 
13 14 
Total Number of Questions from 
Section #2 Correct 
12 9 
Total Number of Questions from 
Section #3 Correct 
9 14 
Total Number of Questions from 
Section #4 Correct 
25 37 
There were a total of 176 questions that could be answered on either of the pre- or post-
education questionnaires (16 questions per questionnaire, and 11 completed questionnaires 
included in the analysis). All analyses were completed using proportions in order to negate the 
biasing impact of the skipped questions on the statistical analysis. Table 1 shows all answers given 
to each questionnaire, and Table 2 shows a comparison of the total counts of the types of answers. 
As shown from this table, the number of correct answers in the post-education questionnaires, 75, 
exceeds the number of correct answers in the pre-education questionnaires, 59. Figure 6 
graphically depicts this comparison using the proportion of correct answers in pre-education 
questionnaires (0.38±0.15) as compared with the post-education questionnaires (0.50±0.15), 
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which shows that this difference is not statistically significant. Table 2 also shows that a 
comparison of the number of incorrect answers between the pre- and post-education questionnaires 
shows a decrease from 76 to 70. Figure 6 shows that the proportion of incorrect answers in pre-
education questionnaires is 0.49±0.15 and is 0.46±0.15 in the post-education questionnaires, which 
again shows that this difference is not statistically significant. Table 2 shows that a comparison of 
the number of “Uncertain” answers between the pre- and post-education questionnaires shows a 
decrease from 19 to 5. Figure 6 shows this with the proportion of “Uncertain” answers in pre-
education questionnaires (0.12±0.10) being greater than that of the post-education questionnaires 
(0.03±0.05), which shows that this difference is not statistically significant. Finally, Table 2 also 
shows that the comparison of the number of skipped questions in the pre-education questionnaire 
and post-education questionnaire shows an increase from 22 to 25 questions. This is graphically 
depicted in Figure 6, which shows that the proportion of skipped questions in pre-education 
questionnaires (0.14±0.11) is less than that of the post-education questionnaires (0.17±0.11), but 
again, this difference is not statistically significant. While data does not show statistically 
significant differences in responses in pre- and post-education questionnaires, trends were 
identified and will be discussed. 
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Figure 6. Comparison of Proportions of All Answer Types in Pre- and Post-Education Questionnaires with 
Error Bars to Show Standard Error (SE) 
 
Additionally, Table 2 shows information about the number of correctly answered questions 
in each of the four sections of the questionnaire. This information is graphically depicted in Figure 
7, which shows a comparison of the proportions of correct answers from each section in the pre- 
and post-education questionnaires. It can be seen that the proportion of correct answers in section 
one did not significantly change (0.43±0.09 and 0.41±0.09). The same can be said for the 
proportion of correct answers in section two, which decreased from 0.30±0.08 to 0.25±0.08, again 
not statistically significant. An increase in the proportion of correct answers was seen in both 
sections three and four (respectively 0.30±0.08 to 0.35±0.09 and 0.48±0.09 to 0.67±0.09), but this 
was not statistically significant.  
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Figure 7. Comparison of Proportions of Correct Answers from Each Questionnaire Section in Pre- and 
Post-Education Questionnaires with Error Bars to Show Standard Error (SE) 
Due to the small sample size and other factors including several skipped questions, seven 
key questions were identified prior to data analysis as being the most descriptive of displaying 
participant knowledge. One question each was identified from questionnaire sections one, two, 
and three, and four questions were identified from section four as being the most representative of 
understanding the topic discussed in each section. Because the bulk of information presented in 
the educational intervention was from section four, more questions were selected from this section 
to provide additional information regarding the participants’ deeper understanding of this topic. 
The key questions selected from each section were question numbers 1, 4, 8, and 13-16 and are 
shown in Table 3. Each participant’s answers are shown to these key questions in Table 4, and the 
number of correct answers to each question in both pre- and post-educational intervention 
questionnaires are shown in Table 5. 
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Table 3. Key Questions by Section 
Section 
Question 
Number 
Question Correct Answer 
1 1 
"An inherited, or genetic, disorder can be passed to 
a child by which of the following people?" 
a. His or her parents 
2 4 "A carrier of an autosomal recessive disorder is:" 
b. Someone who 
does not show 
symptoms of a 
disorder, but whose 
children can have it. 
3 8 
"A mitochondrial disorder can be passed to a child 
by which of the following people?" 
b. The mother 
4 
13 
"MELAS can be passed to a child by which of the 
following people?" 
b. The mother 
14 "Which of the following is true of MELAS?" 
c. A child who has 
MELAS may not 
show all the 
symptoms of 
MELAS. 
15 
"Which of these symptoms is seen in patients with 
MELAS?" 
d. All of the above 
16 
"In general, do women with MELAS-causing 
mitochondrial changes pass these changes on to all 
of their children?" 
a. Yes 
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Table 4. Participant Answers to Key Questions 
Questionnaire # Q1 Q4 Q8 Q13 Q14 Q15 Q16 
Q002.1 S  S  0 1 0 0 S  
Q002.2 S  S  S  S  0 0 S  
Q004.1 1 1 1 1 1 0 0 
Q004.2 1 1 0 1 0 1 0 
Q005.1 1 1 0 0 1 1 0 
Q005.2 1 0 1 1 1 0 1 
Q006.1 1 0 1 1 0 0 0 
Q006.2 1 0 1 1 1 0 1 
Q008.1 IDK 1 0 0 0 0 0 
Q008.2 S  S  0 0 0 0 0 
Q010.1 1 0 1 1 1 0 0 
Q010.2 S  S  0 1 1 1 1 
Q011.1 1 1 1 1 0 1 0 
Q011.2 1 0 1 1 0 1 1 
Q012.1 1 1 S  S  1 0 0 
Q012.2 1 0 1 1 1 1 1 
Q013.1 1 0 0 1 0 1 1 
Q013.2 1 1 0 1 1 1 0 
Q014.1 1 1 1 1 1 1 0 
Q014.2 1 0 1 1 1 1 1 
Q015.1 1 IDK 1 1 1 0 0 
Q015.2 1 0 1 1 1 1 0 
1 = Correct Answer; 0 = Incorrect Answer; IDK = “I am uncertain of the correct answer”; S = Skipped question 
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Table 5. Number of Correct Answers to Key Questions in Pre- and Post-Education Questionnaires 
Key Question 
Number of Correct 
answers in Pre-education 
Questionnaire 
Number of Correct 
answers in Post-education 
Questionnaire 
Question 1 9 8 
Question 4 6 2 
Question 8 6 6 
Question 13 8 9 
Question 14 6 7 
Question  15 4 7 
Question 16 1 6 
 
Figure 8 shows there is variability of undefined statistical significance in the proportion of 
correct answers to the key questions before and after the educational intervention. Rather, 
McNemar’s Test was used to determine the significance of the difference in the proportion of 
correct answers to these key questions between the pre- and post-education questionnaire 
responses. The results of these tests are presented in Table 6. 
 
Table 6. McNemar's Test Results for Differences in Proportions of Correct Answers to Key Questions 
 Two-tailed  
P-value 
Statistically 
Significant? 
Chi 
Squared 
DF Odds 
Ratio 
95% CI 
Question 1 Could not be calculated (more than one discordant value is zero) 
Question 4 0.3711 No 0.800 1 0.250 0.005-2.526 
Question 8 1.0000 No 0.000 1 0.500 0.008-9.605 
Question 13 1.0000 No 0.000 
 
1 Cannot be calculated 
(a discordant value is zero) 
Question 14 1.0000 No 0.000 1 2.000 0.104-117.994 
Question 15 0.3711 No 0.800 1 0.250 0.005-2.526 
Question 16 0.1306 No 2.286 1 6.000 0.728-275.986 
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6.2 COMMUNITY MUTATION FREQUENCY 
At Study Visit One, samples were collected from 14 individuals from the extended family of the 
index patient. Twelve of these participants were adults, and two of them were children of adult 
participants. One participant consented to the study but declined to participate in sample collection 
and the associated testing. All participants were related to the index family through the matriarch 
of the index family except subjects AF004 and AF017, who were married into the family from the 
Amish community. Urine samples were collected from all participants, and blood spots on filter 
cards were collected from all participants except subject AF026, who declined to provide a sample 
for blood heteroplasmy level testing. Prior to sample collection, all participants took part in 
interviews, which began with a confirmation of willingness to consent. During this time, no 
participant who had previously consented declined to confirm consent. 
High-resolution melting (HRM) profiling was completed twice (Trial 1 and Trial 2) by co-
investigator Lina Ghaloul Gonzalez, MD. Trial 1 took place on all samples on November 19, 2014, 
and Trial 2 took place on all samples on November 20, 2014. These results were recorded in 20% 
increments, except for the 5% heteroplasmy level, which was the only dilution made in a 5% 
increment. In order to improve accuracy of the results, the testing was repeated in Trial 3 on 
December 19, 2014 using further dilutions of the control samples. Results of this testing are 
reported in Table 7. This allowed interpretation of results in approximately 10% increments, except 
for the 5% heteroplasmy level, which was the only dilution made in a 5% increment. Examples of 
results from HRM testing are shown in Figure 8.  
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Table 7. Results of Heteroplasmy Testing 
Subject ID 
Urine 
Heteroplasmy 
Trial 1 
Blood 
Heteroplasmy 
Trial 1 
Urine 
Heteroplasmy 
Trial 2 
Blood 
Heteroplasmy 
Trial 2 
Urine 
Heteroplasmy 
Trial 3 
Blood 
Heteroplasmy 
Trial 3 
AF001 40% 10% 40-60% ~10% 40% 10% 
AF002 90-100% ~60% ~100% 40-60% 100% ~60% 
AF003 Not Done Not Done 80-100% ~20% 90% ~30% 
AF004 0% 0% ~0% ~0% 0%* 0% 
AF005 40-60% 10-20% ~40% ~10% ~20%* ~5% 
AF007 N/A N/A N/A N/A N/A N/A 
AF008 Not Done Not Done ~80% ~20% ~80% ~20-30% 
AF009 >~80% 40-60% 60-80% ~40% ~70% ~40% 
AF010 ~60% ~20% ~80% ~20% 70-80% 20% 
AF012 ~70% ~20% 40-60% ~20% ~70%* ~30% 
AF015 60-80% ~20% 80% ~20% 70% ~20% 
AF017 Not Done Not Done 0% 0% 0%* 0% 
AF019 Not Done Not Done ~100% ~80% 100% ~70% 
AF025 ~10% ~0% ~20% 0-5%* ~10%* 0-5% 
AF026 Not Done Not Done ~20%* N/A ~20%* N/A 
AF027 Not Done Not Done 90-100%ꜝ 80% ~90% ~70% 
ꜝ = greater than 90%, and slightly less than 100% 
* = value is slightly shifted from the expected laboratory value
“Not Done” = Sample not run in that trial; N/A = Sample did not provide adequate results for interpretation 
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Figure 8. Selected HRM Profiles from Analysis by Lina Gonzalez, MD 
A. Result of all controls from trial 2 including the wild-type sample and samples with heteroplasmy of 5%, 
10%, 20%, 40%, 60%, 80%, and 100% 
B. 100% wild-type control samples from volunteers 
C. Results of subject AF025’s trial 2 dried blood spot (DBS) HRM testing, approximately 5% heteroplasmy 
D. Results of subject AF001’s trial 2 DBS HRM testing, approximately 10% heteroplasmy 
E. Results of subject AF012’s trial 2 DBS HRM testing, approximately 20% heteroplasmy 
F. Results of subject AF012’s trial 2 urine HRM testing, approximately 40-60% heteroplasmy 
G. Results of subject AF027’s trial 2 DBS HRM testing, approximately 80% heteroplasmy 
H. Results of subject AF002’s trial 2 urine HRM testing, approximately 100% heteroplasmy 
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Table 8. Highest Detected Heteroplasmy Levels in Participants 
Subject ID 
Provided 
Sample? 
Heteroplasmy 
Detected? 
Highest Level 
of 
Heteroplasmy 
Sample 
Tissue 
Type 
AF001 Yes Yes 40-60% urine 
AF002 Yes Yes 100% urine 
AF003 Yes Yes 90% urine 
AF004 Yes No   
AF005 Yes Yes 20%* urine 
AF007 No     
AF008 Yes Yes 80% urine 
AF009 Yes Yes 70% urine 
AF010 Yes Yes 70-80% urine 
AF012 Yes Yes 70%* urine 
AF015 Yes Yes 70% urine 
AF017 Yes No   
AF019 Yes Yes 100% urine 
AF025 Yes Yes 10%* urine 
AF026 Yes Yes 20%* urine 
AF027 Yes Yes >90% urine 
* = value is slightly shifted from the expected laboratory value 
 
The Study Visit two activities occurred on March 21, 2015. The study team met with 
participants to review the results of their MELAS heteroplasmy testing. Results were disclosed to 
some participants individually and to others in nuclear family groups as per their preference. 
Parents of both of the child participants had results disclosed to the parent to confirm 
understanding. The disclosure was made by investigators meeting in pairs with individuals or 
selected immediate family members. Before arriving, each group was assigned to disclose to 
specific participants to ensure that those with the highest levels of heteroplasmy would be speaking 
with a physician to assure that specific treatment and management guidelines for each of those 
individuals was appropriately communicated. All participants were provided with a copy of their 
individual testing results during their counseling session. 
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During the disclosure process, several of the women whose results identified heteroplasmy 
indicated interest in having their children tested. Two of the participants, AF005 and AF025, were 
each accompanied by a daughter for whom they provided consent for testing. These two 
participants also expressed great interest in pursuing testing for their other children, either during 
a home visit or at a planned clinic at Hermitage Hospital.  
Participant AF008 was unable to attend study visit two. However, study staff will follow-
up via mail and/or telephone to provide him with his test results and answer any questions he has 
about management and treatment guidelines. 
For all study participants, a letter summarizing the genetic counseling/results disclosure 
session along with a copy of their test results will be mailed to them. An anonymized example of 
a letter sent to participant is shown in Appendix N. However, each letter was tailored to encompass 
all information discussed in the genetic counseling session.  
6.3 EXTENDED FAMILY PEDIGREE 
Information to construct pedigrees was collected during study visit one interviews. Each interview 
was conducted by an investigator with pedigree-taking experience including, the primary 
investigator, Jerry Vockley, MD, PhD and co-investigators, Catherine Walsh Vockley, MS, 
LCGC; Amy Goldstein, MD; and Afifa Irani, BS. Each interview was conducted with individuals 
or nuclear family members. All interviews began with confirmation of willingness to consent to 
study participation, during which no participant who had previously consented to the study 
declined to confirm consent. Additionally, it was noted that multiple members of the extended 
family who were present declined to participate in interviews and the study as a whole. Each 
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participant was questioned about his or her own health using the MELAS-related symptoms 
checklist (Appendix I), and asked to keep these symptoms in mind when providing information 
about other family members’ health. Prior to the interviews, as a group, participants aided 
investigators in constructing a brief pedigree that provided information on the birth order of the 
index patient’s maternal sibship (the children of AF010) in order to later combine all pedigrees 
constructed during interviews. While taking family history information, all data were recorded, 
but difficulties were encountered in how to report uncertainty. 
Using Progeny 6.0 and Microsoft Office PowerPoint, a pedigree was constructed for the 
extended family related to the index patient through maternal lineage after returning from study 
visit one. This pedigree is not shown here. Rather, a smaller pedigree, shown in Figure 9 includes 
only the index patient’s mother’ sibship. In this pedigree, each member of the sibship is labeled 
with a letter. Additional pedigrees were constructed to provide information about each nuclear 
family and symptoms of mitochondrial disease, and these are shown in Figures 10-14. These 
pedigrees each have a letter in the upper left-hand corner that corresponds to the letters with which 
the siblings in Figure 9 are labeled. 
Because the community historically limits outsiders’ access to their community, any 
interaction with the extended community can only occur with permission of the community elders. 
These study activities were conducted with approval of a community Deacon. However, given 
time constraints of the study, the team was unable to extend the study activity permissions and 
interaction beyond the extended index family. This means that pedigree construction did not 
extend beyond the index family. 
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All MELAS-related clinical features reported in the family are recorded in the pedigree 
key in Figure 9. Health problems that are likely unrelated to MELAS are listed below each 
individual’s pedigree symbol. 
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Figure 9. Extended Maternal Family of Index Patient and Pedigree Key 
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Figure 10. Family A 
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Figure 11. Family B 
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Figure 12. Family C 
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Figure 13. Family D 
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Figure 14. Family E 
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Figure 15. Family F 
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Figure 16. Family G 
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Figure 17. Family H 
68 
 
Figure 18. Family I 
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Figure 19. Family J 
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Figure 20. Family K
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6.4 RESULTS DISCLOSURE VISIT 
During Study Visit Two, or the results disclosure visit, multiple anecdotal interactions 
independently experienced by investigators qualitatively suggested that participants retained a 
substantial amount of information from the education intervention done during Study Visit One. 
The independent teams of investigators disclosing results each had the impression that information 
reviewed and communicated had been well-retained by the majority of participants with whom it 
was shared. One participant, AF005, even indicated that she had retained the educational 
intervention handout provided at the first study visit. Another participant, AF025 expressed clear 
understanding of maternal inheritance and an understanding of the implications of her results for 
treatment and early recognition of symptom development.  
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7.0  DISCUSSION 
7.1 EDUCATIONAL INTERVENTION 
A significant portion of study planning involved designing the educational intervention and 
associated questionnaires. Program planning was utilized to develop the concept of the educational 
intervention composed of both an oral and visual component. This concept was developed through 
the lens of genetic counseling, as clinical genetic counselors typically use visual aids along with 
an oral description of health education concepts for patients. Following the development of the 
educational intervention, a questionnaire was designed, keeping in mind the participant audience, 
to measure the efficacy of the educational intervention. A discussion of the educational 
intervention including discussion of the results of questionnaire responses, the format of the 
educational intervention, limitations and future directions of this part of the study, and an 
evaluation of this method compared to the genetic counseling that took place later in the study 
follows. 
7.1.1 Questionnaire Results 
The aim of the educational intervention was to provide members of an at-risk Amish community 
with information about mitochondrial disease in general and MELAS in particular. Questionnaires 
were used as a tool to measure whether or not this educational intervention was successful. The 
categories of answers within the questionnaire included the following: correct answers, incorrect 
answers, skipped answers, and “Uncertain” answers. These categories were compared to one 
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another using proportions in order to negate the biasing impact of the skipped questions on the 
statistical analysis. These proportions were compared in the pre- and post-educational intervention 
questionnaires to determine if there was a statistically significant difference in the answers before 
and after the educational intervention. A major limitation of this evaluation of statistical 
significance was the small number of participants, which resulted in large standard errors (SEs). 
This ultimately resulted in a lack of statistically significant differences among answers before and 
after the educational intervention. However, upon further evaluation, trends were identified that 
would allow for more qualitative comment on the educational intervention’s efficacy. While the 
questionnaires did not provide statistically significant evidence of increased understanding of 
MELAS and mitochondrial disease, upon returning to the community to disclose results of testing, 
participants anecdotally appeared to demonstrate clear understanding of the basic concepts relayed 
during the educational intervention. This was not confirmed through quantifiable evidence, 
however, investigators thought this to be true based on the interactions between participants and 
disclosing investigators at study visit two. 
7.1.1.1 Analysis of Key Questions 
Due to use of McNemar’s Test for statistical analysis, the consulting statistician noted that 
populating the post-education questionnaires with the answers from the pre-education 
questionnaire, as was requested by two study participants, would diminish the integrity of the 
statistical analysis. Therefore, the questionnaires labelled Q003 and Q007 were removed from 
inclusion in data analysis. Key questions that investigators thought best represented understanding 
of the underlying concepts being queried in each section of the questionnaire were selected prior 
to analysis of the questionnaires. These key questions for each section are shown in Table 3. For 
section one, this was the concept of basic genetics; for section two, this was the concept of 
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autosomal recessive inheritance. For section three, this was the concept of mitochondrial 
inheritance. In section four, each of the four key questions targeted a different concept related to 
MELAS. Question 13 focused on maternal inheritance; question 14 focused on delayed onset of 
symptoms; question 15 dealt with identification of symptoms related to MELAS, and question 16 
pertained to targeted clinical variability and the bottleneck effect as they are related to maternal 
inheritance. 
This educational intervention was designed with the presumption that there was some pre-
existing participant understanding of basic genetics including autosomal recessive inheritance. It 
was thought that the increased prevalence of genetic disorders in the Amish community would 
have predisposed this audience to exposure to information about basic genetics. Question number 
one was included to provide an assessment of this presumption. However, inadequate responses to 
the question limited analysis of this presumption. When analyzing this question, the McNemar’s 
Test calculation could not be completed because there was no change in the number of respondents 
who answered correctly from the pre-education questionnaire to the post-education questionnaire, 
which means there was more than one discordant value equal to zero. While this is not statistically 
significant data from which conclusions can be drawn, it is possible that the lack of difference in 
respondent data is due in combination to the expectation that there was an underlying foundational 
understanding of basic genetics, and the educational intervention did not aim to provide a better 
understanding of basic genetics. Rather, the intervention was designed to utilize an existing 
foundational understanding of basic genetics, and this expectation could be supported by the lack 
of difference in respondent data. 
Analysis of the key question from section two about autosomal recessive inheritance 
showed no difference between the proportion of correct answers in the pre-education questionnaire 
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responses and the proportion of post-education questionnaire responses. However, more detailed 
evaluation of the responses to this question provided valuable insight. Inspection of the pre-
educational intervention questionnaires shows that the number of participants who were familiar 
with autosomal recessive inheritance by name was lower than expected. This may indicate that an 
educational intervention designed to explain maternal inheritance without using autosomal 
recessive inheritance as a foundation may prove more successful for members of this population. 
However, it should also be noted that through interaction during the oral presentation of the 
educational intervention, participants demonstrated an understanding of the risks of having a child 
with an autosomal recessive condition to a couple who previously had an affected child as being 
25%, which supported a prior understanding of this inheritance pattern. Additionally, participants 
verbally confirmed understanding of this inheritance pattern but commented that they had not 
heard of it referred to as being “autosomal recessive.” Perhaps because of this, the use of autosomal 
recessive inheritance as a foundation may have been more effective if it was discussed using 
terminology with which participants were familiar. 
The third section of the questionnaire primarily focused on mitochondrial disease as a class 
of disorders. As with the results of the key question from section two, the responses to the key 
question from section three showed there was no difference between the proportions of correct 
answers in the pre-education questionnaire responses and the post-education questionnaire 
responses. More detailed inspection of responses to this question does not provide clarity about 
trending. 
The fourth section of the questionnaire specifically discussed MELAS. As with the results 
of the key question from sections two and three, the responses to the key question from section 
four showed there was no difference between the proportions of correct answers in the pre-
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education questionnaire responses and the post-education questionnaire responses. More detailed 
inspection of responses to this particular question does not provide clarity about trending. 
However, when using the information in Figure 10 to compare the proportions of correct answers 
in the entire section in the pre-education questionnaire responses and the post-education 
questionnaire responses, there is an increase in the proportion of correct answers after the 
educational intervention. Using the information in Table 5, which shows the number of correct 
answers for the key questions in section four, it is also evident that an increased number of correct 
answers was seen for all of the section four key questions in the post-educational intervention 
questionnaire as opposed to the pre-educational intervention one. This is, again, not a statistically 
significant increase, likely due to the small sample size, but it does help to identify a trend in the 
responses. One possible explanation for the higher number of correct answers on post-education 
questionnaires may be that the respondents found the MELAS component of the educational 
intervention more meaningful, and therefore, this information was better-retained.61 Further, the 
index patient’s family had reached out to maternal relatives and had spoken to them about the 
diagnosis of MELAS in their family, which means that the participants may have had more interest 
in information about MELAS in particular. 
It was also noticed that there was a higher number of correct answers to the key questions 
about basic maternal inheritance in the pre-education questionnaires than the other key questions. 
While not a statistically significant difference, one possible explanation for this is that the 
respondents were a biased population regarding that question. As most participants were related 
through the maternal lineage to the index patient, their presence indicated a general understanding 
that maternal relationships are involved in the inheritance of mitochondrial disorders.  
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7.1.2 Format of Educational Intervention 
When designing the educational intervention, investigators decided the best presentation method 
would be to use a printed, visual handout paired with verbal presentation. This approach was based 
on characteristics of the target audience. These primarily included community characteristics, such 
as lack of access and exposure to electronics and limited schooling and thus a lower literacy rate, 
particularly scientific and genetic literacy. 
It has been reported that acute comprehension problems arise when individuals with a 
history of low literacy are presented with medical or health-related information.62; 63 The handout 
component of the educational intervention was designed to serve as a pictorial representation of 
the information being presented orally in order to overcome this potential barrier posed by the 
lower literacy and scientific education levels of this isolated Amish community. An example of 
steps taken to provide effective visual communication includes the use of color-coding, which has 
been shown to improve processing and integration of presented information.64; 65 Several of the 
diagrams in the handout used color-coding to emphasize different concepts. For example, making 
the mutant mtDNA red throughout allowed for consistency of reference and understanding 
throughout the presentation. Additionally, color-coding was also utilized to more basically 
describe features associated with encephalomyopathy. The verbal delivery of the majority of the 
information in the intervention meant that anyone with a lower literacy level did not have to depend 
on their reading skills to follow the presentation. The verbal presentation also allowed for 
interaction between the participants and the presenter. The participant feedback that resulted from 
this interaction led to additional review of concepts deemed difficult by the community in order to 
ensure participant understanding of the information.  
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7.1.3 Benefits, Limitations, and Future Modifications 
Working with an Amish community to achieve study aims has proven beneficial in several 
ways. While participating in research may sometimes be a burden, this community was very 
welcoming to the study team. The index patient’s family provided access to their home for both 
study visit meetings. The team was graciously welcomed and shared in traditional Amish 
hospitality. Additionally, through investigator interactions with participants, it was clear that 
members of the extended family cared for one another and understood the implications of MELAS 
testing not just for themselves but also for their immediate and extended family members. Working 
with an Amish community also had benefits that were directly related to study outcomes. 
Participants in this community are generally knowledgeable about family and medical history 
information pertaining to themselves, their children, and more extended family relations, thus 
enriching the pedigree construction in aim two. Before interviews, participants were also able to 
aid in construction of a broader pedigree to more clearly elucidate family relationships for 
investigators. Development of the educational intervention was challenging as the team recognized 
the typical limits to schooling in this community and limited exposure to advanced technology. 
However, this was ultimately beneficial in many ways. Moving forward, the educational 
intervention and associated questionnaires are on track to being useful in the general population 
due to being limited to an eighth grade reading level. They can also be more easily adapted to other 
languages and formats because of the simplicity of design and limited number of words. 
As discussed above, members of the Amish community have limited schooling, with most 
community members not participating in formal education beyond the eighth grade, and limited 
exposure to biology and other sciences. The presentation handout was designed to address these 
factors.  However, upon providing each participant with his or her own copy of this handout, it 
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seemed that the educational goals of the study could have been more successfully achieved through 
a different method. During the presentation, rather than following along with their own handouts, 
participants instead focused their attention on the presenter’s handout. It is possible that having 
their own copy was cumbersome or distracting rather than beneficial for some. It did appear that 
when attention was focused on a specific small detail on the handout , participants seemed to turn 
to their own handouts more often. However, this need to focus also resulted in flipping of pages to 
find the correct figure. Based on this observation, one possible alternative way to implement the 
use of the handout would be to use one or two large, poster-sized copies of the handout as a single 
visual aid rather than providing individual copies to each participant. This might allow participants 
to focus more on the information being presented and reduce the need to look at smaller details up 
close because of the increased size of the presenter copy of the handout. Further, a personal copy 
of the handout could then be provided for reference to each participant at the end of the educational 
session. 
An additional barrier to understanding for some participants was their underlying medical 
condition. Some individuals suffered from significant hearing loss, which led to an inability to 
follow along with verbal component of the presentation. At least one participant had loss of 
cognitive function due to strokes and chronic illness, which limited the ability to understand both 
the handout and the verbal presentation. Other ailments, including poor vision, resulted in trouble 
utilizing the visual aids.  
This educational intervention was shared with physicians, genetic counselors, genetic 
counseling students, lay-people, and other healthcare professionals. All these people provided 
feedback on the efficacy of the intervention, and modifications were made accordingly to both the 
handout and the verbal component of the intervention. Due to time constraints and concern for 
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biasing the potential study population, the intervention was not presented to anyone from the study 
population. However, given the Study Visit One experience with the educational intervention in 
the study population, this educational intervention could have benefitted from being presented to 
a group of Amish community members unfamiliar with mitochondrial disease prior to being 
finalized. This would have provided additional insight and input that could not be garnered through 
sharing the presentation with “English” individuals. As previously noted, it was thought by 
investigators that this community would be familiar with autosomal recessive genetic conditions 
and the autosomal recessive inheritance pattern. In actuality, based on both the results of the 
questionnaires and on interactions with participants during the educational intervention, it seems 
the participants with whom the study team primarily communicated may not have had significant 
exposure to these conditions and at the least, had not heard of them referred to as such.  As 
previously discussed, including a discussion of autosomal recessive inheritance was meant to 
provide a framework for thinking about inheritance in general and a lead-in to explaining the 
maternal inheritance pattern of MELAS. However, as the analysis of responses to the pre-
education questionnaire shows, as presented, this was likely not an effective foundation in  this 
community  for thinking about inheritance patterns and understanding maternal inheritance. While 
current study data does not provide evidence for or against utilization of this method, based on 
feedback from the participations, re-designing the intervention so that it focuses solely on maternal 
inheritance before re-implementing this educational intervention may prove beneficial. 
While no statistically significant data resulted from the analysis of the questionnaire data, 
there were data trends that suggested improvements in understanding about MELAS after the 
educational intervention. However, throughout the data analysis, it was evident that additional 
questionnaire piloting would have increased the utility of this questionnaire as a determinant of 
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the efficacy of this educational intervention. While piloting was completed, no one from an Amish 
community was given the opportunity to participate in this activity. This limitation is similar to 
what was encountered with the educational intervention. Given the nature of the relationship 
between the study team and the community, it was thought that obtaining substantial feedback on 
either the questionnaire or the educational intervention was not a realistic option due to limited 
contact with community members other than the index family. Potential for biasing study 
participants was also a concern. In retrospect, it may have been beneficial to approach someone 
from the community but outside the index family to obtain feedback regarding the questionnaire 
prior to its administration. 
7.1.4 Evaluating Increased Understanding of Educational Intervention through Genetic 
Counseling 
There were two different types of interactions during which information about MELAS was 
presented to study participants: an educational intervention and a genetic counseling session. 
Comparisons between these two roles, first as a presenter providing education to a group and 
second as a provider of genetic counseling to one participant or nuclear family at a time, are helpful 
when thinking about approaches to patient education. The genetic counseling session provided a 
better platform for gauging participant understanding, which allowed for adjustments in 
counseling style, word choice, and use of visual aids. This was more difficult to achieve in a larger 
group setting because gauging the individual responses from several people at once posed a 
different set of challenges than doing so one-on-one. One possible reason for it being more 
challenging to assess participant needs in the group setting is that participants may have been more 
willing to ask specific questions that pertained to themselves or their own personal understanding 
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in the one-on-one session when they felt the information would be kept private and confidential. 
An additional possibility is that participants did not have time to process the information from the 
educational session immediately following the educational intervention, and may have used the 
handout and discussion among group members in the interim to provide clarification or additional 
insight into the information. Ultimately, there is no way to determine if the increased 
understanding observed anecdotally by investigators during study visit two was a result of the 
educational intervention, communication among participants, a more individualized genetic 
counseling session, or a combination of these and other factors. Fortunately, during study visit 
two, it seemed to investigators that participants left the genetic counseling sessions with an 
understanding of what their test result meant for themselves and their families. 
7.2 ONE-ON-ONE INTERVIEW SESSIONS 
The information collected from the one-on-one interviews was used to construct a detailed 
extended family pedigree. This pedigree depicts all family relationships and clinical features 
present in these family members, as reported by participants. Information about family members 
who were discussed by more than one of the participants was confirmed as being the same from 
both sources before being added to the pedigree. Overlap of information, however, was an 
uncommon occurrence.  
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7.2.1 Interview Session Format, Limitations, and Future Modifications 
 In each interview, the participant was asked a series of questions about his or her health and was 
then questioned about the health of his or her family members, keeping in mind the same symptoms 
about which they were questioned. This is standard practice when taking a targeted pedigree, and 
all interviewers had previous experience taking targeted pedigrees.58  In general, participants were 
well-informed about the health histories of their immediate family members. However, when 
participants were answering questions about members of their extended family including cousins, 
nieces, nephews, and grandchildren, they sometimes were uncertain about exactly which relatives 
had experienced which symptoms. During these times when participants were providing 
information of which they were unsure, there was no way for interviewers to quantify the level of 
certainty of all information provided or a previously-defined method of including information 
about which participants were unsure. In cases where the participant had expressed uncertainty, it 
was left to the discretion of the interviewer to determine whether or not to record that information, 
and if so, how to express the lower level of certainty associated with only that piece of information. 
There are several possible outcomes of this uncertainty. One outcome may have been under-
recording of clinical features found in the community. Another may be that it could have resulted 
in investigators excluding information about which participants were unsure. Retrospectively, an 
attempt was made to clarify any questionable information in the pedigree with the investigator 
who recorded the information. Attempts were also made to clarify any uncertain medical 
information at the second study visit. To avoid this concern in the future, it would be useful to 
adjust all forms used by investigators when interviewing participants to allow for a space to include 
a lower confidence level in a particular piece of information provided to the investigator. Finally, 
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including a predetermined way to record this information into the pedigree may provide clarity to 
investigators when evaluating for trends in the participant population as a whole. 
7.3 MUTATION FREQUENCY AND CLINICAL FEATURES IN THE 
COMMUNITY 
The HRM profiling method was selected for analysis of heteroplasmy in this population due to its 
cost-efficiency, rapid turnaround time, and proven ability to detect the mutation of interest. It had 
also been demonstrated in previous work that the HRM profiling method could detect mtDNA 
heteroplasmy for the m.3243A>G mutation as low as 5%, which was desirable as investigators 
were unsure of the clinical presentation and the expected heteroplasmy levels for participants. For 
those participants’ samples that returned negative results using this testing, but in whom 
investigators felt there may be low levels of heteroplasmy due to relationships with affected or 
mutation-carrying individuals, additional testing could be performed that would detect 
heteroplasmy levels as low as 1%. However, this was not necessary in this study as all individuals 
in whom investigators expected to detect heteroplasmy had levels greater than 5%. The only two 
participants in whom heteroplasmy was not detected using this method were related to the 
extended family through marriage, and were thus not expected to have heteroplasmy unless there 
were additional kindreds with MELAS in the community. This is notable with regard to the larger 
aim of ascertaining frequencies of the common MELAS mutation in the general northwestern 
Pennsylvania Amish community. However, due to limitations to access of the community and the 
small sample size of participants for the study, it is not possible to utilize data from this study to 
determine the frequency of this mutation in the community. Rather, this work will require more 
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extensive community engagement, which may follow after a more long-standing relationship 
between the community and investigators has been established. One gratifying outcome of this 
project has been the establishment of an Amish Genetics Clinic in Mercer County sponsored by 
the Children’s Hospital of Pittsburgh.  
The pedigrees portray the array of clinical features with which members of this family are 
affected. As is consistent with a maternal inheritance pattern, all participants who were related 
through the maternal lineage to the index patient had some detectable level of heteroplasmy, but 
as is shown in the pedigrees, the clinical presentation of this mutation varies dramatically in this 
community. The reported clinical features in this community correlate with previously published 
features of MELAS and general mitochondrial disease.15; 16 As expected, individuals with higher 
levels of heteroplasmy had more symptoms of MELAS. For example, the index patient, AF019 
experienced the most symptoms of any of the family members, and she had a urine heteroplasmy 
level of approximately 100%. Other family members with lower levels of heteroplasmy, such as 
AF025, showed fewer or no symptoms. Also as expected, it was noted that individuals with 
intermediate levels of heteroplasmy, in the 40-70% range, had dramatic variability in symptoms. 
Some individuals in this range, such as AF012 had fewer features of the condition, while others, 
such as AF009 had several symptoms of MELAS. One potential underlying cause of this clinical 
variability may be the different levels of heteroplasmy in different tissues. For example, a 
seemingly less affected individual may have higher levels of heteroplasmy in tissues that do not 
require significant amounts of energy to be produced, such as the skin, which may result in the 
individual not appearing to have many symptoms. If, however, an individual has high levels of 
heteroplasmy in a tissue with high energy demands, such as the brain or muscles, this individual 
might display more classic symptoms of MELAS. During interviews, investigators questioned 
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participants about their healthcare as related to symptoms of MELAS. Few participants sought 
medical care for any of the symptoms, and for those who did, records could not be reviewed due 
to participants generally not having enough information to complete a release for medical 
information form. Because investigators did not perform physical exams and because, largely, 
participants did not have significant prior screening or imaging for many features of MELAS, such 
as cardiac or neurological imaging, investigators are not able to definitively rule out the potential 
presence of some clinical features in all participants.  Additional clinical follow-up is planned. 
7.3.1 Heteroplasmy Testing in Different Sample Types 
For this study, samples collected included blood spots and urine samples from all but one 
participant, who declined to have blood drawn. This allowed for comparison between the results 
of testing in the two sample types. Due to the logistical difficulty of collecting a third sample type, 
cheek mucosal samples were excluded from this study, although inclusion of that sample would 
have provided additional data for comparison of efficacy of mutation detection in different tissues. 
All cases showed higher heteroplasmy in DNA derived from urine samples than in DNA derived 
from blood samples (Table 8). As previously noted, the mutational load in blood leukocytes is 
depleted over time. The majority of participants were adults, giving ample time for that depletion 
to have occurred. This is supported by data from analysis of the children’s samples, as analysis of 
both their blood and urine sample heteroplasmy levels provided similar results to one another. 
These results are consistent with previous findings that compared the heteroplasmy levels in 
different sample types.19; 20 
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7.4 PUBLIC HEALTH IMPLICATIONS 
The prevalence of mitochondrial disease is estimated to be approximately 1 in 5,000 individuals.48 
However, mitochondrial conditions are often difficult to recognize and diagnose. In order to make 
a diagnosis, clinicians must first be able to categorize the patient’s phenotype as falling within the 
ever-increasing spectrum of recognized symptoms associated with mitochondrial disease, then 
they must navigate the variety of diagnostic laboratory tests available to provide sufficient 
evidence to diagnose the etiology of these symptoms.66 The novel diagnosis of mitochondrial 
disease in an Amish community by physicians at the Children’s Hospital of Pittsburgh of UPMC 
is anecdotal support of this concept. It was not until a patient had a severe complication of the 
condition, a stroke, and thus was referred to a tertiary care center for management and evaluation, 
that the constellation of symptoms in the patient and family were recognized as potentially due to 
a mitochondrial disorder and diagnostic testing was done. As demonstrated through this extended 
pedigree, many family members are affected with individual or less severe symptoms that were 
not previously recognized as being associated with mitochondrial disease; they were considered 
to be isolated findings by the patients’ health care providers. More specifically, in this Amish 
family, 13 of 15 tested family members, and in fact 13 of 13 blood relatives, all except five of 
whom were previously not known to have mitochondrial disease were found to have MELAS and 
can now seek medical intervention. MELAS was clearly under-recognized based on this study in 
this Amish community. There are patient populations with features of mitochondrial disease, such 
as diabetes, hearing loss, and cardiovascular clinics. Given the fact that many individuals who 
suffer from mitochondrial disease are misdiagnosed with other conditions, screening those 
populations who have mild features of mitochondrial disease, like the participants of this study 
did, may provide an underlying diagnosis of mitochondrial disease that could guide treatment and 
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management and provide information about prognosis and early symptom recognition.12; 66; 67 
While it is not possible to predict the percent of these patients who would have mitochondrial 
disease, based on the work done through this study on one community, it is possible that patients 
would be found who could benefit from therapeutic intervention aimed at treating the symptoms 
of mitochondrial disease. 
7.4.1 Disease Awareness 
Many studies have cited the benefits of raising awareness and providing education about a 
disorder, and how that can lead to earlier diagnosis and treatment and therefore better outcomes.68-
72 There are organizations such as the United Mitochondrial Disease Foundation that strive to 
promote both “research and education about the diagnosis, treatment, and cure of mitochondrial 
disorders.”73  These organizations can serve as a resource to the general population about the latest 
news and information relating to mitochondrial disease research and information. Organizations 
such as these could be utilized in a public health effort to educate and to promote awareness the 
general population about mitochondrial disease.  
One aim of this study was to design an educational intervention to promote awareness and 
understanding of MELAS and mitochondrial disease in general. While that intervention was 
designed to serve the Amish community, or, at least, a community with relatively lower literacy, 
different needs may or may not be required in the general population. Given the overall 
recommendation to develop materials for general patient education at a sixth to eighth grade 
reading level and the content of the handout, it would provide a foundation for general population 
educational materials.74; 75 Several components of the existing intervention could be utilized and 
modified to achieve the goal of educating the general public, including information about the 
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structure and function of the mitochondria, the mitochondrial genome, maternal inheritance, and 
clinical features associated with mitochondrial disease.  
7.4.2 Integration of the Educational Intervention in the General Population 
A major modification that will facilitate adaptation of this intervention for use in the general 
population will be to re-format it for distribution, either online or in the form of a pamphlet or 
brochure that can be easily distributed. It will not be feasible to provide an oral presentation to all 
recipients of the information, although any printed or online version could also be used in 
conjunction with individualized genetic counseling. In cases where genetic counseling is not 
possible, the intervention could be adapted online to include audio files containing this information 
or in print by using more descriptive diagrams. There has been considerable research completed 
in recent years focusing on the types of health information consumers are obtaining online.76-80 
The conclusions drawn from this research indicate that consumers are turning more and more to 
the Internet for credible, trustworthy, accurate health information. However, some of this research 
has also shown that health information consumers struggle with identifying which sources of 
information are indeed credible, trustworthy, and accurate.78; 80 Providing health information 
consumers with access to this information online, in clinicians’ offices, and in other information 
repositories such as state and federal departments of health or through appropriate condition-
specific support organizations may provide the general population with access they would have 
otherwise lacked, along with validation of the accuracy of the materials themselves. 
This study can serve as a model for investigation of an effective educational intervention 
for the general population. One limitation of measuring the efficacy of the educational intervention 
designed in this study, as noted, is the lack of pre-testing of the questionnaire used as a measuring 
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tool. Therefore, before integrating a modified educational intervention into a larger group, pilot 
testing to determine its efficacy would be advantageous. A questionnaire can be developed that is 
modeled on studies that have used questionnaires aimed at measuring efficacy of health 
information resources in the general population. In addition to performing additional testing to 
confirm the efficacy of the questionnaire as a measuring tool, the questionnaire would have to be 
utilized in more expansive research in larger study populations representative of the general 
population to determine the efficacy of the new proposed educational intervention. Ideally, this 
research would also include significant involvement at each step of the process from an expert in 
questionnaire design and analysis specifically aimed at evaluating the efficacy of education for 
members of the general population.  
7.4.3 Public Health Impact of Education about Mitochondrial Disease in the Amish 
Community 
As seen at the Clinic for Special Children, as community awareness of the presence of genetic 
disorders increased, so did the utilization of services at the clinic, which has ultimately resulted in 
earlier diagnosis and treatment for patients affected with genetic disorders.2; 3; 34 Furthermore, one 
of the significant community effects of this earlier diagnosis and treatment has been reduction in 
the financial burden of healthcare.2 Better prognoses for children with these disorders have also 
resulted from earlier diagnosis and treatment.3 Similarly, it is hoped that earlier diagnosis of 
mitochondrial disease yields improved outcomes for identified patients.55 The magnitude of 
improvements is only tempered by uncertainties about the prevalence of mitochondrial disease in 
Amish communities. In this community alone, in addition to MELAS, a patient unrelated to this 
index family has been diagnosed with MELAS/Leigh Overlap syndrome caused by a mtDNA 
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mutation in the ND5 subunit of respiratory chain complex I.81 Additional patients affected by 
mitochondrial disease may be identified in Northwestern Pennsylvania and in Lancaster County, 
PA among those Amish patients who have yet to receive a specific diagnosis. 
7.4.4 Public Health Competencies 
Throughout the work of this study, several public health competencies were developed and 
utilized. Primarily, this study revolved around cross-cutting competencies including 
communication and informatics, diversity and culture, leadership, public health biology, and 
program planning.82 Within each of these cross-cutting competencies, several skills were used or 
developed during the process of this study.  
 When considering communication and informatics, a primary aim in this study was 
achieved through demonstrating effective written and oral skills for communicating with different 
audiences within the context of professional public health activities. This competency was 
developed through the creation of the educational intervention, the study visits, and through the 
writing of the related thesis document. Skills developed and practiced within the competency of 
diversity and culture were the use of basic concepts and skills involved in culturally appropriate 
community engagement and consideration of situations where culture-specific needs could result 
in more effective modifications or adaptations of a health intervention. The former occurred during 
and leading up to the study visits when study team members targeted study activities directly 
toward the Amish community being visited. The latter took place in a more reflective manner after 
the completion of the study when determining the benefits and limitations of particular interactions 
during study visits and communication that took place before visits.  
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Leadership skills developed particularly focused on articulation of an achievable mission 
and vision as well as engaging in dialogue and learning from others to advance public health goals. 
These skills have been constantly developing and improving throughout the entirety of this study 
beginning with the development of a thesis proposal and an IRB application and continuing 
through the data-gathering and study visits until now with the development of this thesis document. 
Public health biology was paramount in this study as one of the focal points was explaining 
how genetics and genomics affect disease processes and public health policy and practice. It was 
an objective that through providing an educational intervention about MELAS and mitochondrial 
disease, many members of a community increased their understanding of these concepts. aLater 
reflection about the future directions of this work after data analysis has provided an opportunity 
to consider how the findings of this study may inform changes in public health policy and practice.  
Finally, programming planning was a significant component of the process of this study. 
Of particular relevance was explaining, defining and differentiating among goals, measurable 
objectives, related activities, and expected outcomes for this study and potential subsequent public 
health programs. Another particularly relevant competency is differentiating between qualitative 
and quantitative evaluation methods in relation to their strengths, limitations, and appropriate uses. 
These two concepts coalesced in the development of the educational intervention and related 
questionnaires and the data analysis and interpretation that followed. Afterward, considerations 
were made toward explaining how the findings of a program evaluation can be used, particularly 
as it relates to the educational intervention and its implementation in the general population. 
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8.0  CONCLUSIONS AND FUTURE DIRECTIONS 
8.1 CONCLUSIONS 
After the identification of previously unrecognized mitochondrial disease in a northwestern 
Pennsylvania Amish community, this study was designed with three specific aims. The first was 
to characterize the incidence and clinical features of the common MELAS mutation in the 
northwestern Pennsylvania Amish community. This aim was met in the extended family of the 
index patient; however, there are plans to continue gathering incidence information among other 
members of the whole community. While additional testing and characterization will continue, 
this study has validated the first hypothesis, i.e. that there is a higher incidence of the m.3243A>G 
mutation in the MT-TL1 gene in this community than was clinically recognized before this study. 
Through testing, thirteen individuals tested positive for this mutation, whereas prior to the study, 
there were only five individuals noted. The second aim was to construct a detailed extended 
pedigree of the index family and other key kinships in the community. This aim was met partially 
through completion of the pedigree in the extended family of the index patient. Patient 
ascertainment and pedigree development will continue as additional community members are 
recruited to consent to the study protocol through interaction with clinicians at the Hermitage 
Hospital Clinic. An IRB amendment will be required for this process. Finally, the third aim was to 
develop and assess the efficacy of an educational intervention designed to increase understanding 
of MELAS and mitochondrial disease in this community. In conjunction with this aim, the second 
hypothesis stated that this educational intervention would increase understanding of MELAS and 
mitochondrial disease in this community. While the questionnaires administered did not provide 
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statistically significant evidence of this, upon returning to the community to disclose results of 
testing, participants demonstrated increased understanding of the basic concepts relayed during 
the educational intervention. This was not confirmed through quantifiable evidence, however, 
qualitative impressions through counseling sessions and conversation suggested increased 
knowledge and understanding of MELAS, its symptoms, and mitochondrial inheritance. 
8.2 FUTURE DIRECTIONS 
This study was completed to meet part of the requirement for a Master’s degree, and thus, out of 
necessity, there were several limitations placed on its scope. There are several ongoing and planned 
future studies that build on the presented work. These include outreach to the community at large 
to determine how prevalent mitochondrial disease, and MELAS in particular, is in this and other 
Amish communities. This work would also include a comparison of the prevalence of 
mitochondrial disease in other Amish communities outside of the northwestern Pennsylvania 
region to the prevalence found in the study population. It could also expand to include general 
population screening for mitochondrial diseases in individuals from the general population with 
mild phenotypes. Further elucidation of the pedigree for this kindred and other northwestern 
Pennsylvania Amish kindreds, and potential familial links to other Amish communities is planned 
and may lead to additional outreach to other Amish communities. Ultimately, further studies could 
be completed to link this information about family and community relationships to existing 
databases of Amish genealogy, which could be utilized for other studies in the future. Finally, a 
larger whole genome screen of random population members will serve to identify genetic risk in 
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the community more broadly, alerting care providers to possible diagnoses and leading to more 
expedient diagnoses and prompt therapy. 
8.2.1 Community Preferences for Health Education  
In this study, two major methods of communicating health education were utilized with 
participants. The first occurred during Study Visit One and was a group setting educational session. 
The second was private interviews between an individual or nuclear family and a healthcare 
professional. Through both interactions, the aim was to provide participants with information 
about MELAS including its clinical features and inheritance pattern. Even though both methods 
had the same aim, during the group educational intervention, this information was presented in a 
more general way, and in the interviews, it was more personalized to the particular participant 
including sharing of participant test results. Based on investigators’ perceptions of patient 
understanding, the educational intervention did provide participants with basic information about 
the condition and inheritance pattern. However, it was evident at the time of disclosure that 
participants still had questions related more specifically to themselves. This two-tiered approach 
to information provision parallels what has been done in other settings. For example, in prenatal 
counseling, genetic counselors use group sessions for providing general information and one-on-
one sessions for individualized counseling. However, it would be interesting to clarify with the 
community that this approach is efficacious for them. 
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8.2.2 Additional MELAS Heteroplasmy Testing in This Community 
Analysis of samples collected in the extended family of the index patient in this Amish community 
led to the identification of many individuals with heteroplasmy. This knowledge, along with the 
occurrences of large families, raises concern about additional community members being at risk 
for having unidentified heteroplasmy. Therefore, use of urine heteroplasmy testing as a screening 
tool for individuals in the community who may or may not be directly related to the index family, 
could identify individuals who are in need of specific clinical follow-up. If this additional testing 
takes place, particular attention should be given to gathering pedigree information to clarify the 
relationships among all individuals found to have heteroplasmy for the purpose of identifying other 
at-risk community members. 
8.2.3 General Population Screening for Mitochondrial Disease in Individuals with Mild 
Phenotypes 
The results of this study confirm that there are individuals in this Amish community with 
previously unrecognized m.3243A>G mutations. As discussed previously, it is similarly suspected 
that some individuals in the general population who have mild symptoms or limited family history 
of features seen in MELAS may be living with unrecognized mtDNA mutations. There was 
significant variability in clinical presentations of individuals with mutations in this community, 
which supports the under-diagnosis of individuals with MELAS. Identifying populations with a 
mild MELAS or mitochondrial disease phenotype, such as those with conditions thought to be 
isolated, through clinics such as hearing loss, diabetes, and cardiovascular clinics might lead to 
identification of populations where mitochondrial disease is under-diagnosed. Because 
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undiagnosed mitochondrial disease has been discovered in one population, it is possible that 
similarly undiagnosed individuals may exist in the general population.  
8.2.4 Extended Community Pedigree Construction 
The construction of a comprehensive pedigree of the Amish communities in Northwestern 
Pennsylvania can provide guidance for identifying families and individuals at risk for certain 
inherited conditions. While this study yielded an adequately constructed pedigree of one extended 
family, it provides limited information on the pedigrees of those who are related to the index family 
through marriage. Because of this, additional community pedigree construction would be required 
to determine if there are more families at risk for being heteroplasmic for the m.3243A>G MELAS 
or other mitochondrial mutations. In addition, further testing would provide information to 
members of those families who are at risk for passing the MELAS mutation to their children if the 
mutation is identified. Constructing this extended pedigree may also provide additional 
information on the genealogy of this community and may help link it to previously-completed 
genealogy maps.  
8.2.5 Whole Exome Sequencing and the Amish 
Population-based whole exome sequencing (WES) or whole genome sequencing (WGS) has not 
been reported in any Amish community in the United States. A collection of WES or WGS 
information about members of this community could lead to further identification of disease-
associated genes in Amish communities. It could be used to supplement existing ancestral 
information for Amish communities, reinforcing links among many Amish communities in the 
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United States, which allows for the collection and preservation of this historic knowledge.67; 83-85 
WES or WGS in Amish communities could provide information about genetic sequences that are 
identical by descent and unique to this population, which may contribute to other advances in 
genetic medicine benefitting themselves, other Amish communities, the general population, and 
the field of genetic medicine.83; 85 Particularly in the absence of MELAS or other mitochondrial 
disorders and when individuals are exhibiting symptoms of disease, this may provide a diagnosis, 
which could be used to guide future management and treatment as well as provide prognosis 
information. 
 WES or WGS in this and other Amish communities might provide information about the 
different founder populations of Amish settlements. Identifying these links between communities 
might, in turn, provide information about conditions for which specific settlements or populations 
are more at risk. This information could lead to more specific offering and appropriate utilization 
of services based on projected needs. 
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APPENDIX A: IRB APPROVAL LETTER 
The IRB approved this study on November 13, 2014 per this letter. 
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APPENDIX B: INITIAL CONTACT LETTER 
This letter was sent to the index family as the first step of correspondence regarding this study. 
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APPENDIX C: LETTER OF PERMISSION FROM COMMUNITY DEACON 
This is a letter from Deacon Albert Kuhns, who provided permission for the study to be conducted 
in the Amish community of interest. 
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APPENDIX D: PRE-EDUCATIONAL SESSION QUESTIONNAIRE 
This pre-education questionnaire was provided in a booklet format to participants. 
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APPENDIX E: ADULT INFORMED CONSENT FORM 
This is the consent form signed by adult participants. 
115 
116 
117 
118 
119 
120 
121 
122 
APPENDIX F: CHILD INFORMED CONSENT FORM 
This is the consent form signed by parents to provide consent for their child participant. 
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APPENDIX G: EDUCATIONAL INTERVENTION HANDOUT 
This was the handout used as a visual aid for the educational intervention. Each participant had a 
copy on which to follow along with the presenting investigator. 
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APPENDIX H: POST-EDUCATIONAL SESSION QUESTIONNAIRE 
This is the post-educational questionnaire distributed to participants after the educational 
intervention.
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APPENDIX I: MELAS-RELATED SYMPTOMS CHECKLIST 
This list of symptoms associated with MELAS and mitochondrial disease was used by 
investigators to question historians about the presence of these symptoms in themselves and their 
family members. 
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APPENDIX J: FOLLOW-UP LETTER FOR STUDY VISIT TWO 
This letter was sent to the index family on December 5, 2014 requesting contact to coordinate 
Study Visit Two for results disclosure and genetic counseling regarding the completed 
heteroplasmy testing 
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APPENDIX K: SECOND FOLLOW-UP LETTER FOR STUDY VISIT TWO 
This letter was sent on January 9, 2015 to follow up from the first letter sent in December because 
that letter went unanswered. 
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APPENDIX L: RESPONSE LETTER REGARDING STUDY VISIT TWO 
This letter was sent in response to a missed phone call from the index family, during which the 
patriarch requested that heteroplasmy results for all participants be mailed in individual sealed 
envelopes to the index family for distribution to extended family members at their next gathering. 
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APPENDIX M: RESULTS DISCLOSURE VISIT PROCEDURE OUTLINE 
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APPENDIX N: TEMPLATE GENETIC COUNSELING SUMMARY LETTER 
This is the template of the summary of genetic counseling letter that was sent to each participant 
to whom results were disclosed. 
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